<?xml version="1.0" encoding="UTF-8"?>
<Bundle xmlns="http://hl7.org/fhir">
  <id value="bundle-paxlovidfctablets"/>
  <meta>
    <versionId value="1"/>
    <lastUpdated value="2023-05-01T00:00:00Z"/>
    <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
  </meta>
  <language value="en"/>
  <identifier>
    <system value="https://www.fda.gov/"/>
    <value value="paxlovid"/>
  </identifier>
  <type value="document"/>
  <timestamp value="2023-05-01T00:00:00Z"/>
  <entry>
    <fullUrl value="urn:uuid:a2366b4a-263d-4819-893b-9dde4209bec8"/>
    <resource>
      <Composition>
        <id value="a2366b4a-263d-4819-893b-9dde4209bec8"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
        </meta>
        <language value="en"/>
        <version value="1"/>
				<date value="2023-05-01T00:00:00Z"/>
				<status value="final"/>
        <contained>
          <Binary>
            <id value="image1"/>
            <contentType value="image/png"/>
            <data value= "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"/>
          </Binary>
        </contained>
        <contained>
          <Binary xmlns="http://hl7.org/fhir">
            <id value="image2"/>
            <contentType value="image/png"/>
            <data value= "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"/>
          </Binary>
        </contained>
        <extension url="http://hl7.org/fhir">
					<valueReference>
						<reference value="#image1" />
					</valueReference>
				</extension>
        <extension url="http://hl7.org/fhir">
					<valueReference>
						<reference value="#image2" />
					</valueReference>
				</extension>
        <identifier>
          <system value="https://www.fda.gov/"/>
          <value value="a2366b4a-263d-4819-893b-9dde4209bec8"/>
        </identifier>
        <type>
          <coding>
            <system value="2.16.840.1.113883.6.1"/>
            <code value="34391-3"/>
            <display value="HUMAN PRESCRIPTION DRUG LABEL"/>
          </coding>
        </type>
        <subject>
          <reference value="urn:uuid:446915fa-e64e-45cb-8a98-ddd47a53193b"/>
        </subject>
        <author>
          <reference value="urn:uuid:7ac0d617-838e-4ae0-ad3c-c3be9004e921"/>
          <reference value="urn:uuid:a7ea98b8-b6b5-48a2-bdbf-944593efe4b8"/>
        </author>
        <title value="USPI Paxlovid nirmatrelvir ritonavir tablets"/>
        <section>
          <title value="BOXED WARNING"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value="34066-1"/>
              <display value="BOXED WARNING SECTION"/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <div id="BOXED"></div>
              <p style="text-align:center"><b>WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID</b></p>
                <ul>
                  <li><b>PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events [see <a href="#section4">Contraindications (4)</a>, <a href="#section5">Warnings and Precautions (5.1)</a>, and <a href="#section7">Drug Interactions (7)</a>].</b></li>
                  <li><b>Prior to prescribing PAXLOVID: 1) Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring [see <a href="#section7">Drug Interactions (7)</a>].</b></li>
                  <li><b>Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed [see <a href="#section5">Warnings and Precautions (5.1)</a>, <a href="#section7">Drug Interactions (7)</a>, and <a href="#section7">Clinical Studies (14)</a>].</b></li>
                </ul>
            </div>
          </text>
          <section>
            <title value="1	INDICATIONS AND USAGE"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34067-9"/>
                <display value="INDICATIONS AND USAGE SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section1"></div>
                <p><b>1	INDICATIONS AND USAGE</b></p>
                <p>PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID 19, including hospitalization or death.</p>
                <p><u>Limitations of Use</u></p>
                <p>PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19 [see <a href="#section14">Clinical Studies (14.3)</a>].</p>
              </div>
            </text>
          </section>
          <section>
            <title value="2	DOSAGE AND ADMINISTRATION"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34068-7"/>
                <display value="DOSAGE AND ADMINISTRATION SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section2"></div>
                <p><b>2	DOSAGE AND ADMINISTRATION</b></p>
                <p><b>2.1	Important Dosage and Administration Information</b></p>
                <p>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. There are two different dose packs available:</p>
                <ul>
                <li>PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 300 mg;100 mg [see <a href="#section2">Dosage and Administration (2.2)</a>].</li>
                <li>PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 150 mg;100 mg for patients with moderate renal impairment [see <a href="#section2">Dosage and Administration (2.3)</a>].</li>
                </ul>
                <p>Nirmatrelvir must be co-administered with ritonavir. Failure to correctly co-administer nirmatrelvir with ritonavir may result in plasma levels of nirmatrelvir that are insufficient to achieve the desired therapeutic effect.</p>
                <p>Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID [see <a href="#section2">Dosage and Administration (2.2, 2.3)</a>]. Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.</p>
                <p>The 5-day treatment course of PAXLOVID should be initiated as soon as possible after a diagnosis of COVID 19 has been made, and within 5 days of symptom onset even if baseline COVID-19 symptoms are mild. Should a patient require hospitalization due to severe or critical COVID-19 after starting treatment with PAXLOVID, the patient should complete the full 5 day treatment course per the healthcare provider’s discretion.</p>
                <p>If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.</p>
                <p>PAXLOVID (both nirmatrelvir and ritonavir tablets) can be taken with or without food [see <a href="#section12">Clinical Pharmacology (12.3)</a>]. The tablets should be swallowed whole and not chewed, broken, or crushed.</p>
                <p><b>2.2	Recommended Dosage</b></p>
                <p>The recommended dosage for PAXLOVID is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all 3 tablets taken together orally twice daily for 5 days.</p>
                <p><b>2.3	Dosage in Patients with Renal Impairment</b></p>
                <p>No dosage adjustment is recommended in patients with mild renal impairment (eGFR ≥60 to &lt;90 mL/min).</p>
                <p>In patients with moderate renal impairment (eGFR ≥30 to &lt;60 mL/min), the dosage of PAXLOVID is 150 mg nirmatrelvir (one 150 mg tablet) and 100 mg ritonavir (one 100 mg tablet) with both tablets taken together twice daily for 5 days [see <a href="#section16">How Supplied/Storage and Handling (16)</a>]. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions [see <a href="#section17">Patient Counseling Information (17)</a>].</p>
                <p>PAXLOVID is not recommended in patients with severe renal impairment (eGFR &lt;30 mL/min) until more data are available; the appropriate dosage for patients with severe renal impairment has not been determined [see <a href="#section8">Use in Specific Populations (8.6)</a> and <a href="#section12">Clinical Pharmacology (12.3)</a>].</p>
                <p><b>2.4	Use in Patients with Hepatic Impairment</b></p>
                <p>No dosage adjustment is needed in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.</p>
                <p>No pharmacokinetic or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe (Child-Pugh Class C) hepatic impairment; therefore, PAXLOVID is not recommended for use in patients with severe hepatic impairment [see <a href="#section8">Use in Specific Populations (8.7)</a>].</p>
              </div>
            </text>
          </section>
          <section>
            <title value="3	DOSAGE FORMS AND STRENGTHS"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="43678-2"/>
                <display value="DOSAGE FORMS AND STRENGTHS SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section3"></div>
                <p><b>3	DOSAGE FORMS AND STRENGTHS</b></p>
                <p>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets [see <a href="#section16">How Supplied/Storage and Handling (16)</a>].</p>
                <lu>
                  <li>Nirmatrelvir is supplied as oval, pink immediate-release, film-coated tablets debossed with “PFE” on one side and “3CL” on the other side. Each tablet contains 150 mg of nirmatrelvir.</li>
                  <li>Ritonavir is supplied as white or white to off-white film-coated tablets uniquely identified by the color, shape, and debossing. Each tablet contains 100 mg of ritonavir.</li>
                </lu>
              </div>
            </text>
          </section>
          <section>
            <title value="4	CONTRAINDICATIONS"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34070-3"/>
                <display value="CONTRAINDICATIONS SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section4"></div>
                <p><b>4. CONTRAINDICATIONS</b></p>
                <p>PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product.</p>
                <p>PAXLOVID is contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. There are certain other drugs for which concomitant use with PAXLOVID should be avoided and/or dose adjustment, interruption, or therapeutic monitoring is recommended. Drugs listed in this section are a guide and not considered a comprehensive list of all drugs that may be contraindicated with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor like PAXLOVID [see <a href="#section7">Drug Interactions (7.3)</a>]:</p>
                <p>- Drugs that are primarily metabolized by CYP3A for which elevated concentrations are associated with serious and/or life-threatening reactions [see <a href="#section7">Drug Interactions (7.3)</a>]:</p>
                <lu>
                  <li>Alpha1-adrenoreceptor antagonist: alfuzosin</li>
                  <li>Antianginal: ranolazine</li>
                  <li>Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine</li>
                  <li>Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 1, <a href="#section7">Interactions (7.3)</a>])</li>
                  <li>Antipsychotics: lurasidone, pimozide</li>
                  <li>Benign prostatic hyperplasia agents: silodosin</li>
                  <li>Cardiovascular agents: eplerenone, ivabradine</li>
                  <li>Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine</li>
                  <li>HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 1, <a href="#section7">Interactions (7.3)</a>])</li>
                  <li>Immunosuppressants: voclosporin</li>
                  <li>Microsomal triglyceride transfer protein inhibitor: lomitapide</li>
                  <li>Migraine medications: eletriptan, ubrogepant</li> 
                  <li>Mineralocorticoid receptor antagonists: finerenone</li> 
                  <li>Opioid antagonists: naloxegol</li> 
                  <li>PDE5 inhibitor: sildenafil (Revatio®) when used for pulmonary arterial hypertension (PAH)</li> 
                  <li>Sedative/hypnotics: triazolam, oral midazolam</li> 
                  <li>Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin</li> 
                  <li>Vasopressin receptor antagonists: tolvaptan</li> 
                </lu>
                <p>- Drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer [see <a href="#section7">Drug Interactions (7.3)</a>]:</p>
                <lu>
                  <li>Anticancer drugs: apalutamide</li>
                  <li>Anticonvulsant: carbamazepine, phenobarbital, primidone, phenytoin</li>
                  <li>Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor</li>
                  <li>Antimycobacterials: rifampin, rifapentine</li>
                  <li>Herbal products: St. John's Wort (hypericum perforatum)</li>
                </lu>
              </div>
            </text>
          </section>
          <section>
            <title value="5	WARNINGS AND PRECAUTIONS"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="43685-7"/>
                <display value="WARNINGS AND PRECAUTIONS"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section5"></div>
                <p><b>5. WARNINGS AND PRECAUTIONS</b></p>
                <p><b>5.1 Risk of Serious Adverse Reactions Due to Drug Interactions</b></p>
                <p>Initiation of PAXLOVID, which contains ritonavir, a strong CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PAXLOVID, may increase plasma concentrations of medications metabolized by CYP3A. Medications that induce CYP3A may decrease concentrations of PAXLOVID. These interactions may lead to:</p>
                <lu>
                  <li>Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications.</li>
                  <li>Loss of therapeutic effect of PAXLOVID and possible development of viral resistance.</li>
                </lu>
                <p>Severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with PAXLOVID. The most commonly reported concomitant medications resulting in serious adverse reactions were calcineurin inhibitors (e.g., tacrolimus, cyclosporine), followed by calcium channel blockers.</p>
                <p>Prior to prescribing PAXLOVID, review all medications taken by the patient to assess potential drug-drug interactions and determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring (e.g., calcineurin inhibitors) [see <a href="#section4">Contraindications (4)</a> and <a href="#section7">Drug Interactions (7)</a>]. See Table 1 for clinically significant drug interactions, including contraindicated drugs. Drugs listed in Table 1 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID.</p>
                <p>Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed [see <a href="#section7">Drug Interactions (7)</a> and <a href="#section14">Clinical Studies (14)</a>].</p>
                <p><b>5.2 Hypersensitivity Reactions</b></p>
                <p>Anaphylaxis, serious skin reactions (including toxic epidermal necrolysis and Stevens-Johnson syndrome), and other hypersensitivity reactions have been reported with PAXLOVID [see <a href="#section6">Adverse Reactions (6.1)</a>]. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care.</p>
                <p><b>5.3 Hepatotoxicity</b></p>
                <p>Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients with pre existing liver diseases, liver enzyme abnormalities, or hepatitis.</p>
                <p><b>5.4 Risk of HIV-1 Resistance Development</b></p>
                <p>Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection [see <a href="#section4">Contraindications (4)</a>, and <a href="#section7">Interactions (7)</a>].</p>
              </div>
              </text>
          </section>
          <section>
            <title value="6	ADVERSE REACTIONS"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34084-4"/>
                <display value="ADVERSE REACTIONS SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section6"></div>
                <p><b>6	ADVERSE REACTIONS</b></p>
                <p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p>
                <lu>
                  <li>Hypersensitivity reactions [see <a href="#section5">Warnings and Precautions (5.2)</a>]</li>
                </lu>
              </div>
            </text>
          </section>
          <section>
            <title value="6.1	Clinical Trials Experience"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="90374-0"/>
                <display value="CLINICAL TRIALS EXPERIENCE SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml"> 
                <p><b>6.1	Clinical Trials Experience</b></p>
                <p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
                <p>The safety of PAXLOVID is based on two Phase 2/3 randomized, placebo-controlled trials in symptomatic adult subjects 18 years of age and older with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Subjects in both studies received PAXLOVID (nirmatrelvir/ritonavir 300 mg/100 mg) or placebo every 12 hours for 5 days for the treatment of mild-to-moderate COVID-19 within 5 days of symptom onset [see <a href="#section14">Clinical Studies (14)</a>]:</p>
                <lu>
                  <li>Trial C4671005 (EPIC-HR) enrolled subjects who were at high risk for progression to severe disease.</li>
                  <li>Trial C4671002 (EPIC-SR) enrolled subjects who were at standard risk for progression to severe disease (previously unvaccinated subjects at standard risk or fully vaccinated subjects with at least 1 risk factor for progression to severe disease).</li>
               </lu>
               <p>Adverse reactions were those reported while subjects were on study medication and through 28 days after the last dose of study treatment.</p>
               <p>In Trial C4671005 (EPIC-HR), 1,038 subjects received PAXLOVID and 1,053 subjects received placebo. The most common adverse reactions (≥1% incidence in the PAXLOVID group and occurring at a greater frequency than in the placebo group) were dysgeusia (5% and &lt;1%, respectively) and diarrhea (3% and 2%, respectively).</p>
               <p>Among vaccinated or unvaccinated subjects at standard risk or fully vaccinated subjects with at least 1 risk factor for progression to severe disease in Trial C4671002 (EPIC-SR), 540 subjects received PAXLOVID and 528 subjects received placebo. The adverse reactions observed were consistent with those observed in EPIC HR</p>
               <p><u>Emergency Use Authorization Experience in Subjects with COVID-19</u></p>
               <p>The following adverse reactions have been identified during use of PAXLOVID under Emergency Use Authorization.</p>
                <p><i>Immune System Disorders</i>: Anaphylaxis, hypersensitivity reactions [see <a href="#section5">Warnings and Precautions (5.2)</a>]</p>
                <p><i>Skin and Subcutaneous Tissue Disorders</i>: Toxic epidermal necrolysis, Stevens-Johnson syndrome [see <a href="#section5">Warnings and Precautions (5.2)</a>]</p>
                <p><i>Nervous System Disorders</i>: Headache</p>
                <p><i>Vascular Disorders</i>: Hypertension</p>
                <p><i>Gastrointestinal Disorders</i>: Abdominal pain, nausea, vomiting</p>
                <p><i>General Disorders and Administration Site Conditions</i>: Malaise</p>
              </div>
              </text>
          </section>
          <section>
            <title value="7	DRUG INTERACTIONS"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34073-7"/>
                <display value="DRUG INTERACTIONS section"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section7"></div>
                <p><b>7	DRUG INTERACTIONS</b></p>
                <p><b>7.1	Potential for PAXLOVID to Affect Other Drugs</b></p>
                <p>PAXLOVID (nirmatrelvir co-packaged with ritonavir) is a strong inhibitor of CYP3A, and an inhibitor of CYP2D6, P-gp and OATP1B1. Co-administration of PAXLOVID with drugs that are primarily metabolized by CYP3A and CYP2D6 or are transported by P-gp or OATP1B1 may result in increased plasma concentrations of such drugs and increase the risk of adverse events. Co administration of PAXLOVID with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events is contraindicated [see <a href="#section4"> Contraindications (4)</a> and <a href="#section7">Drug Interactions (7.3) )</a>  Table 1]. Co administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 1. </p>
                <p><b>7.2	Potential for Other Drugs to Affect PAXLOVID</b></p>
                <p>Nirmatrelvir and ritonavir are CYP3A substrates; therefore, drugs that induce CYP3A may decrease nirmatrelvir and ritonavir plasma concentrations and reduce PAXLOVID therapeutic effect [see <a href="#section4">Contraindications (4) </a> and <a href="#section7">Drug Interactions (7.3) </a> Table 1].</p>
                <p><b>7.3	Established and Other Potentially Significant Drug Interactions</b></p>
                <p>Table 1 provides a listing of clinically significant drug interactions, including contraindicated drugs [see <a href="#section4">Contraindications (4) </a> and <a href="#section5">Warnings and Precautions (5.1) </a>]. Drugs listed in Table 1 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.</p>
                <body>
                  <h5>Table 1: Established and Other Potentially Significant Drug Interactions</h5>
                  <table ID="reftable1" border="1" width="95%">
                    <col width="21%"/>
                    <col width="24%"/>
                    <col width="21%"/>
                    <col width="34%"/>
                    <thead>
                       <tr>
                          <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                             <content styleCode="bold">Drug Class</content>
                          </th>
                          <th align="center" styleCode="Rrule Botrule Toprule " valign="bottom">
                             <content styleCode="bold">Drugs within Class</content>
                          </th>
                          <th align="center" styleCode="Rrule Botrule Toprule " valign="bottom">
                             <content styleCode="bold">Effect on Concentration</content>
                          </th>
                          <th align="center" styleCode="Rrule Botrule Toprule " valign="bottom">
                             <content styleCode="bold">Clinical Comments</content>
                          </th>
                       </tr>
                    </thead>
                    <tbody>
                       <tr>
                          <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                             <paragraph>Alpha 1-<br/>adrenoreceptor antagonist</paragraph>
                          </td>
                          <td styleCode="Rrule Toprule Botrule " valign="top">
                             <paragraph>alfuzosin</paragraph>
                          </td>
                          <td styleCode="Rrule Toprule Botrule " valign="top">
                             <paragraph>↑ alfuzosin</paragraph>
                          </td>
                          <td styleCode="Rrule Toprule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential hypotension <content styleCode="italics">[see see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Alpha 1-<br/>adrenoreceptor antagonist</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>tamsulosin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ tamsulosin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Avoid concomitant use with PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Antianginal</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>ranolazine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ ranolazine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for serious and/or life-threatening reactions <content styleCode="italics">[see see <a href="#section4"> Contraindications (4) </a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Antiarrhythmics</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>amiodarone, <br/>dronedarone, <br/>flecainide, <br/>propafenone, <br/>quinidine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ antiarrhythmic</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for cardiac arrhythmias <content styleCode="italics">[see see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Antiarrhythmics</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>lidocaine (systemic),<br/>disopyramide</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ antiarrhythmic</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anticancer drugs</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>apalutamide</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↓ nirmatrelvir/ritonavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see see <a href="#section4"> Contraindications (4) </a>].</content>
                             </paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anticancer drugs</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>abemaciclib, <br/>ceritinib,<br/>dasatinib, <br/>encorafenib,<br/>ibrutinib, <br/>ivosidenib, <br/>neratinib, <br/>nilotinib, <br/>venetoclax,<br/>vinblastine, <br/>vincristine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ anticancer drugs</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Avoid co-administration of encorafenib or ivosidenib due to potential risk of serious adverse events such as QT interval prolongation. Avoid use of neratinib, venetoclax or ibrutinib.<br/>
                                <br/>Co-administration of vincristine and vinblastine may lead to significant hematologic or gastrointestinal side effects.<br/>
                                <br/>For further information, refer to individual product label for anticancer drug.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Anticoagulants </paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>warfarin</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑↓ warfarin</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Closely monitor international normalized ratio (INR) if co-administration with warfarin is necessary.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top"/>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>rivaroxaban</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ rivaroxaban</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Increased bleeding risk with rivaroxaban. Avoid concomitant use.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top"/>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>dabigatran<sup>a</sup></paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ dabigatran</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Increased bleeding risk with dabigatran. Depending on dabigatran indication and renal function, reduce dose of dabigatran or avoid concomitant use. Refer to the dabigatran product label for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>apixaban</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ apixaban</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Combined P-gp and strong CYP3A inhibitors increase blood levels of apixaban and increase the risk of bleeding. Dosing recommendations for co-administration of apixaban with PAXLOVID depend on the apixaban dose. Refer to the apixaban product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anticonvulsants</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>carbamazepine<sup>a</sup>,<br/>phenobarbital,<br/>primidone,<br/>phenytoin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↓ nirmatrelvir/ritonavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anticonvulsants</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>clonazepam</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ anticonvulsant</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>A dose decrease may be needed for clonazepam when co-administered with PAXLOVID and clinical monitoring is recommended.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Antidepressants</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>bupropion</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↓ bupropion and active metabolite hydroxy-bupropion </paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Monitor for an adequate clinical response to bupropion. </paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>trazodone</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ trazodone</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Adverse reactions of nausea, dizziness, hypotension, and syncope have been observed following co-administration of trazodone and ritonavir. A lower dose of trazodone should be considered. Refer to trazadone product label for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Antifungals</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>voriconazole</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↓ voriconazole</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Avoid concomitant use of voriconazole.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top"/>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>ketoconazole, <br/>isavuconazonium sulfate,<br/>itraconazole<sup>a</sup>
                             </paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ ketoconazole<br/>↑ isavuconazonium sulfate<br/>↑ itraconazole</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Refer to ketoconazole, isavuconazonium sulfate, and itraconazole product labels for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ nirmatrelvir/ritonavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>A nirmatrelvir/ritonavir dose reduction is not needed.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anti-gout</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>colchicine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ colchicine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anti-HIV protease inhibitors</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>atazanavir,<br/>darunavir,<br/>tipranavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ protease inhibitor</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>For further information, refer to the respective protease inhibitors' prescribing information.<br/>
                                <br/>Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events<content styleCode="italics">.</content>
                             </paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anti-HIV</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>efavirenz,<br/>maraviroc,<br/>nevirapine,<br/>zidovudine,<br/>bictegravir/ <br/>emtricitabine/ <br/>tenofovir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ efavirenz<br/>↑ maraviroc<br/>↑ nevirapine<br/>↓ zidovudine<br/>↑ bictegravir<br/>↔ emtricitabine<br/>↑ tenofovir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>For further information, refer to the respective anti-HIV drugs prescribing information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Anti-infective</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>clarithromycin,<br/>erythromycin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ clarithromycin<br/>↑ erythromycin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Refer to the respective prescribing information for anti-infective dose adjustment.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Antimycobacterial</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>rifampin,<br/>rifapentine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↓ nirmatrelvir/ritonavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance. Alternate antimycobacterial drugs such as rifabutin should be considered <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Antimycobacterial</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>bedaquiline</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ bedaquiline</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Refer to the bedaquiline product label for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>rifabutin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ rifabutin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Refer to rifabutin product label for further information on rifabutin dose reduction.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Antipsychotics</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>lurasidone,<br/>pimozide</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ lurasidone<br/>↑ pimozide</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to serious and/or life-threatening reactions such as cardiac arrhythmias <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Antipsychotics</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>quetiapine</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ quetiapine</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>If co-administration is necessary, reduce quetiapine dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>clozapine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ clozapine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>If co-administration is necessary, consider reducing the clozapine dose and monitor for adverse reactions.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Benign prostatic hyperplasia agents</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>silodosin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ silodosin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for postural hypotension <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Calcium channel blockers</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>amlodipine, <br/>diltiazem,<br/>felodipine,<br/>nicardipine,<br/>nifedipine,<br/>verapamil</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ calcium channel blocker</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.<br/>
                                <br/>If co-administered, refer to individual product label for calcium channel blocker for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Cardiac glycosides</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>digoxin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ digoxin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Caution should be exercised when co-administering PAXLOVID with digoxin, with appropriate monitoring of serum digoxin levels.<br/>
                                <br/>Refer to the digoxin product label for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Cardiovascular agents</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>eplerenone</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ eplerenone</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Co-administration with eplerenone is contraindicated due to potential for hyperkalemia <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>ivabradine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ ivabradine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration with ivabradine is contraindicated due to potential for bradycardia or conduction disturbances <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Cardiovascular agents</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>aliskiren,<br/>ticagrelor,<br/>vorapaxar<br/>
                                <br/>clopidogrel</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ aliskiren<br/>↑ ticagrelor<br/>↑ vorapaxar<br/>
                                <br/>↓ clopidogrel active metabolite</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Avoid concomitant use with PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>cilostazol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ cilostazol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Dosage adjustment of cilostazol is recommended. Refer to the cilostazol product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Corticosteroids primarily metabolized by CYP3A</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>betamethasone,<br/>budesonide,<br/>ciclesonide,<br/>dexamethasone,<br/>fluticasone,<br/>methylprednisolone,<br/>mometasone,<br/>triamcinolone</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ corticosteroid</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration with corticosteroids (all routes of administration) of which exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing’s syndrome and adrenal suppression. However, the risk of Cushing’s syndrome and adrenal suppression associated with short-term use of a strong CYP3A inhibitor is low.<br/>
                                <br/>Alternative corticosteroids including beclomethasone, prednisone, and prednisolone should be considered.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Cystic fibrosis transmembrane conductance regulator potentiators</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>lumacaftor/ivacaftor</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↓ nirmatrelvir/ritonavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>].</content>
                             </paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Cystic fibrosis transmembrane conductance regulator potentiators</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>ivacaftor<br/>elexacaftor/tezacaftor/<br/>ivacaftor<br/>
                                <br/>tezacaftor/ivacaftor</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ ivacaftor<br/>↑ elexacaftor/tezacaftor/<br/>ivacaftor<br/>
                                <br/>↑ tezacaftor/ivacaftor</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Reduce dosage when co-administered with PAXLOVID. Refer to individual product labels for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Dipeptidyl peptidase 4 (DPP4) inhibitors</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>saxagliptin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ saxagliptin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Dosage adjustment of saxagliptin is recommended. Refer to the saxagliptin product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Endothelin receptor antagonists</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>bosentan</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ bosentan<br/>↓ nirmatrelvir/ritonavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Discontinue use of bosentan at least 36 hours prior to initiation of PAXLOVID.<br/>
                                <br/>Refer to the bosentan product label for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Ergot derivatives</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>dihydroergotamine,<br/>ergotamine,<br/>methylergonovine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ dihydroergotamine<br/>↑ ergotamine<br/>↑ methylergonovine</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Hepatitis C direct acting antivirals</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>elbasvir/grazoprevir</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ antiviral</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Increased grazoprevir concentrations can result in alanine transaminase (ALT) elevations.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top"/>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>glecaprevir/pibrentasvir</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top"/>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Avoid concomitant use of glecaprevir/pibrentasvir with PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top"/>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>ombitasvir/paritaprevir/ ritonavir and dasabuvir</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top"/>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Refer to the ombitasvir/paritaprevir/ritonavir and dasabuvir label for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>sofosbuvir/velpatasvir/ voxilaprevir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Refer to the sofosbuvir/velpatasvir/voxilaprevir product label for further information.<br/>Patients on ritonavir-containing HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or HCV drug adverse events with concomitant use<content styleCode="italics">.</content>
                             </paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Herbal products</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>St. John's Wort (<content styleCode="italics">hypericum perforatum</content>)</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↓ nirmatrelvir/ritonavir</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>HMG-CoA reductase inhibitors</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>lovastatin,<br/>simvastatin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ lovastatin<br/>↑ simvastatin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for myopathy including rhabdomyolysis <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.<br/>
                                <br/>If treatment with PAXLOVID is considered medically necessary, discontinue use of lovastatin and simvastatin at least 12 hours prior to initiation of PAXLOVID, during the 5 days of PAXLOVID treatment, and for 5 days after completing PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>HMG-CoA reductase inhibitors</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>atorvastatin,<br/>rosuvastatin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ atorvastatin<br/>↑ rosuvastatin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Consider temporary discontinuation of atorvastatin and rosuvastatin during treatment with PAXLOVID. Atorvastatin and rosuvastatin do not need to be withheld prior to or after completing PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Hormonal contraceptive</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>ethinyl estradiol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↓ ethinyl estradiol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>An additional, non-hormonal method of contraception should be considered during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Immunosuppressants</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>voclosporin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ voclosporin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for acute and/or chronic nephrotoxicity <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Immunosuppressants</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>calcineurin inhibitors:<br/>cyclosporine,<br/>tacrolimus</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>
                                <br/>↑ cyclosporine<br/>↑ tacrolimus</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Avoid concomitant use of calcineurin inhibitors with PAXLOVID when close monitoring of immunosuppressant concentrations is not feasible. If co-administered, dose adjustment of the immunosuppressant and close and regular monitoring for immunosuppressant concentrations and adverse reactions are recommended during and after treatment with PAXLOVID. Obtain expert consultation to appropriately manage the complexity of this coadministration <content styleCode="italics">[see <a href="#section5">Warnings and Precautions (5.1)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>mTOR inhibitors:<br/>everolimus,<br/>sirolimus</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>
                                <br/>↑ everolimus<br/>↑ sirolimus</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>
                                <br/>Avoid concomitant use of everolimus and sirolimus and PAXLOVID.<br/>
                                <br/>Refer to the individual immunosuppressant product label and latest guidelines for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Janus kinase (JAK) inhibitors</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>tofacitinib</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ tofacitinib</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Dosage adjustment of tofacitinib is recommended. Refer to the tofacitinib product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>upadacitinib</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ upadacitinib</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Dosing recommendations for co-administration of upadacitinib with PAXLOVID depends on the upadacitinib indication. Refer to the upadacitinib product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Long-acting beta-adrenoceptor agonist</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>salmeterol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ salmeterol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Avoid concomitant use with PAXLOVID. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Microsomal triglyceride transfer protein (MTTP) inhibitor</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>lomitapide</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ lomitapide</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for hepatotoxicity and gastrointestinal adverse reactions <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Migraine medications</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>eletriptan</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ eletriptan</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Co-administration of eletriptan within at least 72 hours of PAXLOVID is contraindicated due to potential for serious adverse reactions including cardiovascular and cerebrovascular events <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>ubrogepant</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ ubrogepant</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration of ubrogepant with PAXLOVID is contraindicated due to potential for serious adverse reactions <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Migraine medications</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>rimegepant</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ rimegepant</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Avoid concomitant use with PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Mineralocorticoid receptor antagonists</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>finerenone</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ finerenone</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for serious adverse reactions including hyperkalemia, hypotension, and hyponatremia <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Muscarinic receptor antagonists</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>darifenacin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ darifenacin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>The darifenacin daily-dose should not exceed 7.5 mg when co-administered with PAXLOVID. Refer to the darifenacin product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Narcotic analgesics</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>fentanyl,<br/>hydrocodone,<br/>oxycodone,<br/>meperidine</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ fentanyl<br/>↑ hydrocodone<br/>↑ oxycodone<br/>↑ meperidine</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression) is recommended when fentanyl, hydrocodone, oxycodone, or meperidine is concomitantly administered with PAXLOVID. If concomitant use with PAXLOVID is necessary, consider a dosage reduction of the narcotic analgesic and monitor patients closely at frequent intervals. Refer to the individual product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>methadone</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↓ methadone</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Monitor methadone-maintained patients closely for evidence of withdrawal effects and adjust the methadone dose accordingly.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Neuropsychiatric agents</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>suvorexant</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ suvorexant</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Avoid concomitant use of suvorexant with PAXLOVID.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>aripiprazole,<br/>brexpiprazole,<br/>cariprazine,<br/>iloperidone,<br/>lumateperone,<br/>pimavanserin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ aripiprazole<br/>↑ brexpiprazole<br/>↑ cariprazine<br/>↑ iloperidone<br/>↑ lumateperone<br/>↑ pimavanserin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Dosage adjustment of aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, and pimavanserin is recommended. Refer to individual product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Opioid antagonists</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>naloxegol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ naloxegol</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to the potential for opioid withdrawal symptoms <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Pulmonary hypertension agents (PDE5 inhibitors)</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>sildenafil (Revatio<sup>®</sup>)</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ sildenafil</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration of sildenafil with PAXLOVID is contraindicated for use in pulmonary hypertension due to the potential for sildenafil associated adverse events, including visual abnormalities hypotension, prolonged erection, and syncope <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Pulmonary hypertension agents (PDE5 inhibitors)</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>tadalafil (Adcirca<sup>®</sup>)</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ tadalafil</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Avoid concomitant use of tadalafil with PAXLOVID for pulmonary hypertension.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Pulmonary hypertension agents (sGC stimulators)</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>riociguat</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ riociguat</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Dosage adjustment is recommended for riociguat when used for pulmonary hypertension. Refer to the riociguat product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Erectile dysfunction agents (PDE5 inhibitors)</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>avanafil</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ avanafil</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>Do not use PAXLOVID with avanafil because a safe and effective avanafil dosage regimen has not been established.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>sildenafil,<br/>tadalafil,<br/>vardenafil</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ sildenafil<br/>↑ tadalafil<br/>↑ vardenafil</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Dosage adjustment is recommended for use of sildenafil, tadalafil or vardenafil with PAXLOVID when used for erectile dysfunction. Refer to individual product label for more information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Sedative/hypnotics </paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>triazolam, <br/>oral midazolam<sup>a</sup>
                             </paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ triazolam<br/>↑ midazolam</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for extreme sedation and respiratory depression <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule " valign="top">
                             <paragraph>Sedative/hypnotics</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>buspirone,<br/>clorazepate,<br/>diazepam,<br/>estazolam,<br/>flurazepam,<br/>zolpidem</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>↑ sedative/hypnotic</paragraph>
                          </td>
                          <td styleCode="Rrule " valign="top">
                             <paragraph>A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top"/>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>midazolam (administered parenterally)</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ midazolam</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration of midazolam (parenteral) should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.<br/>
                                <br/>Refer to the midazolam product label for further information.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Lrule Botrule " valign="top">
                             <paragraph>Serotonin receptor 1A agonist/ serotonin receptor 2A antagonist</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>flibanserin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ flibanserin</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for hypotension, syncope, and CNS depression <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                       <tr>
                          <td styleCode="Rrule Botrule Lrule " valign="top">
                             <paragraph>Vasopressin receptor antagonists</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>tolvaptan</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>↑ tolvaptan</paragraph>
                          </td>
                          <td styleCode="Rrule Botrule " valign="top">
                             <paragraph>Co-administration contraindicated due to potential for dehydration, hypovolemia and hyperkalemia <content styleCode="italics">[see <a href="#section4">Contraindications (4)</a>]</content>.</paragraph>
                          </td>
                       </tr>
                    </tbody>
                 </table>
              </body>
            <p><sup>a</sup>.	See <a href="#section12">Pharmacokinetics, Drug Interaction Studies Conducted with Nirmatrelvir and Ritonavir (12.3).</a></p>
              </div>
            </text>
          </section>
          <section>
            <title value="8	USE IN SPECIFIC POPULATIONS"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="43684-0"/>
                <display value="USE IN SPECIFIC POPULATIONS SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <div id="section8"></div>
              <p><b>8	USE IN SPECIFIC POPULATIONS</b></p>
              </div>
              </text>
          </section>
          <section>
            <title value="8.1	Pregnancy"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="42228-7"/>
                <display value="PREGNANCY SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>8.1	Pregnancy</b></p>
              <p><u>Risk Summary</u></p>
              <p>Available data on the use of nirmatrelvir during pregnancy are insufficient to evaluate for a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published observational studies on ritonavir use in pregnant women have not identified an increase in the risk of major birth defects. Published studies with ritonavir are insufficient to identify a drug associated risk of miscarriage (<i>see Data</i>). There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (<i>see Clinical Considerations</i>).</p>
              <p>In an embryo-fetal development study with nirmatrelvir, reduced fetal body weights following oral administration of nirmatrelvir to pregnant rabbits were observed at systemic exposures (AUC) approximately 11 times higher than clinical exposure at the approved human dose of PAXLOVID. No other adverse developmental outcomes were observed in animal reproduction studies with nirmatrelvir at systemic exposures (AUC) greater than or equal to 3 times higher than clinical exposure at the approved human dose of PAXLOVID (<i>see Data</i>).</p>
              <p>In embryo-fetal developmental studies with ritonavir, no evidence of adverse developmental outcomes was observed following oral administration of ritonavir to pregnant rats and rabbits at systemic exposures (AUC) 5 (rat) or 8 (rabbits) times higher than clinical exposure at the approved human dose of PAXLOVID (<i>see Data</i>). </p>
              <p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </p>
              <p><u>Clinical Considerations</u></p>
              <p><i>Disease-associated Maternal and/or Embryo-fetal Risk</i></p>
              <p>COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death.</p>
              <p><u>Data</u></p>
              <p><i>Human Data</i></p>
              <p><u><i>Ritonavir</i></u></p>
              <p>Based on prospective reports to the antiretroviral pregnancy registry of live births following exposure to ritonavir-containing regimens (including over 3,500 live births exposed in the first-trimester and over 3,500 live births exposed in the second and third trimesters), there was no difference in the rate of overall birth defects for ritonavir compared with the background birth defect rate of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The prevalence of birth defects in live births was 2.4% [95% confidence interval (CI): 1.9%, 2.9%] following first-trimester exposure to ritonavir-containing regimens and 2.9% (95% CI: 2.4%, 3.5%) following second and third trimester exposure to ritonavir-containing regimens. While placental transfer of ritonavir and fetal ritonavir concentrations are generally low, detectable levels have been observed in cord blood samples and neonate hair.</p>
              <p><i>Animal Data</i></p>
              <p><u><i>Nirmatrelvir</i></u></p>
              <p>Embryo-fetal developmental (EFD) toxicity studies were conducted in pregnant rats and rabbits administered oral nirmatrelvir doses of up to 1,000 mg/kg/day during organogenesis [on Gestation Days (GD) 6 through 17 in rats and GD 7 through 19 in rabbits]. No biologically significant developmental effects were observed in the rat EFD study. At the highest dose of 1,000 mg/kg/day, the systemic nirmatrelvir exposure (AUC <sub>24</sub>) in rats was approximately 9 times higher than clinical exposures at the approved human dose of PAXLOVID. In the rabbit EFD study, lower fetal body weights (9% decrease) were observed at 1,000 mg/kg/day in the absence of significant maternal toxicity findings. At 1,000 mg/kg/day, the systemic exposure (AUC<sub>24</sub>) in rabbits was approximately 11 times higher than clinical exposures at the approved human dose of PAXLOVID. No other significant developmental toxicities (malformations and embryo-fetal lethality) were observed up to the highest dose tested, 1,000 mg/kg/day. No developmental effects were observed in rabbits at 300 mg/kg/day resulting in systemic exposure (AUC<sub>24</sub>) approximately 3 times higher than clinical exposures at the approved human dose of PAXLOVID. A pre- and postnatal developmental (PPND) study in pregnant rats administered oral nirmatrelvir doses of up to 1,000 mg/kg/day from GD 6 through Lactation Day (LD) 20 showed no adverse findings. Although no difference in body weight was noted at birth when comparing offspring born to nirmatrelvir-treated versus control animals, a decrease in the body weight of offspring was observed on Postnatal Day (PND) 17 (8% decrease) and PND 21 (up to 7% decrease) in the absence of maternal toxicity. No significant differences in offspring body weight were observed from PND 28 to PND 56. The maternal systemic exposure (AUC<sub>24</sub>) at 1,000 mg/kg/day was approximately 9 times higher than clinical exposures at the approved human dose of PAXLOVID. No body weight changes in the offspring were noted at 300 mg/kg/day, where maternal systemic exposure (AUC<sub>24</sub>) was approximately 6 times higher than clinical exposures at the approved human dose of PAXLOVID.</p>
              <p><u><i>Ritonavir</i></u></p>
              <p>Ritonavir was administered orally to pregnant rats (at 0, 15, 35, and 75 mg/kg/day) and rabbits (at 0, 25, 50, and 110 mg/kg/day) during organogenesis (on GD 6 through 17 in rats and GD 6 through 19 in rabbits). No evidence of teratogenicity due to ritonavir was observed in rats and rabbits at systemic exposures (AUC) 5 (rats) or 8 (rabbits) times higher than exposure at the approved human dose of PAXLOVID. Increased incidences of early resorptions, ossification delays, and developmental variations, as well as decreased fetal body weights were observed in rats in the presence of maternal toxicity, at systemic exposures (AUC) approximately 10 times higher than exposure at the approved human dose of PAXLOVID. In rabbits, resorptions, decreased litter size, and decreased fetal weights were observed at maternally toxic doses, at systemic exposures greater than 8 times higher than exposure at the approved human dose of PAXLOVID. In a PPND study in rats, administration of 0, 15, 35, and 60 mg/kg/day ritonavir from GD 6 through PND 20 resulted in no developmental toxicity, at ritonavir systemic exposures greater than 10 times the exposure at the approved human dose of PAXLOVID.</p>
           </div>
              </text>
          </section>
          <section>
            <title value="8.2	Lactation"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="77290-5"/>
                <display value="LACTATION SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>8.2	Lactation</b></p>
              <p><u>Risk Summary</u></p>
              <p>There are no available data on the presence of nirmatrelvir in human or animal milk, the effects on the breastfed infant, or the effects on milk production. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir (<i>see Data</i>). Limited published data reports that ritonavir is present in human milk. There is no information on the effects of ritonavir on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PAXLOVID and any potential adverse effects on the breastfed infant from PAXLOVID or from the underlying maternal condition. Breastfeeding individuals with COVID 19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID 19.</p>
              <p><u>Data</u></p>
              <p>In the PPND study, transiently lower body weight (up to 8%) was observed in the offspring of pregnant rats administered nirmatrelvir at maternal systemic exposure (AUC<sub>24</sub>) approximately 9 times higher than clinical exposures at the approved human dose of PAXLOVID. No body weight changes in the offspring were noted at maternal systemic exposure (AUC<sub>24</sub>) approximately 6 times higher than clinical exposures at the approved human dose of PAXLOVID.</p>
              </div>
              </text>
          </section>
          <section>
            <title value="8.3	Females and Males of Reproductive Potential "/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="77291-3"/>
                <display value="FEMALES AND MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p><b>8.3	Females and Males of Reproductive Potential</b></p>
                <p><u>Contraception</u></p>
                <p>Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception [see <a href="#section7">Drug Interactions (7.3)</a>].</p>
              </div>
            </text>
        </section>
        <section>
          <title value="8.4	Pediatric Use"/>
          <code>
            <coding>
              <system value="2.16.840.1.113883.6.1"/>
              <code value="34081-0"/>
              <display value="PEDIATRIC USE SECTION"/>
            </coding>
          </code>
          <text>
            <status value="generated"/>
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>8.4	Pediatric Use</b></p>
              <p>The optimal dose of PAXLOVID has not been established in pediatric patients.</p>
            </div>
          </text>
      </section>
      <section>
        <title value="8.5	Geriatric Use"/>
        <code>
          <coding>
            <system value="2.16.840.1.113883.6.1"/>
            <code value="34082-8"/>
            <display value="GERIATRIC USE SECTION"/>
          </coding>
        </code>
        <text>
          <status value="generated"/>
          <div xmlns="http://www.w3.org/1999/xhtml">
            <p><b>8.5	Geriatric Use</b></p>
            <p>Clinical studies of PAXLOVID include subjects 65 years of age and older and their data contributes to the overall assessment of safety and efficacy [see <a href="#section6">Adverse Reactions (6.1) </a> and <a href="#section14">Clinical Studies (14.1) </a>]. Of the total number of subjects in the integrated dataset consisting of EPIC-HR and EPIC-SR who were randomized to and received PAXLOVID (N=1,578), 165 (10%) were 65 years of age and older and 39 (2%) were 75 years of age and older. No overall differences in safety were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in safety between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
          </div>
        </text>
    </section> 
          <section>
            <title value="8.6	Renal Impairment"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="88828-9"/>
                <display value="RENAL IMPAIRMENT SUBSECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>8.5	Geriatric Use</b></p>
              <p>Renal impairment increases nirmatrelvir exposure, which may increase the risk of PAXLOVID adverse reactions. No dosage adjustment is recommended in patients with mild renal impairment (eGFR ≥60 to &lt;90 mL/min). Reduce the PAXLOVID dosage in patients with moderate renal impairment (eGFR ≥30 to &lt;60 mL/min). PAXLOVID is not recommended for use in patients with severe renal impairment (eGFR &lt;30 mL/min) or patients with end stage renal disease (eGFR &lt;15 mL/min) receiving dialysis until more data are available. The appropriate dosage for patients with severe renal impairment has not been determined [see <a href="#section2">Dosage and Administration (2.3) </a> and <a href="#section12">Clinical Pharmacology (12.3) </a>]. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions [see <a href="#section12">Patient Counseling Information (17) </a>].</p>
              </div>
              </text>
          </section>
          <section>
            <title value="8.7	Hepatic Impairment"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="88829-7"/>
                <display value="HEPATIC IMPAIRMENT SUBSECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>8.7	Hepatic Impairment</b></p>
              <p>No dosage adjustment of PAXLOVID is recommended for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. No pharmacokinetic or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe (Child-Pugh Class C) hepatic impairment, therefore, PAXLOVID is not recommended for use in patients with severe (Child-Pugh Class C) hepatic impairment [see <a href="#section5">Warnings and Precautions (5.3) </a> and <a href="#section12">Clinical Pharmacology (12.3) </a>].</p>
              </div>
              </text>
          </section>
          <section>
            <title value="10	OVERDOSAGE"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34088-5"/>
                <display value="OVERDOSAGE SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <div id="section10"></div>
              <p><b>10	OVERDOSAGE</b></p>
              <p>Treatment of overdose with PAXLOVID should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with PAXLOVID.</p>
            </div>
          </text>
          </section>
          <section>
            <title value="11	DESCRIPTION"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34089-3"/>
                <display value="DESCRIPTION SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
                <div id="section11"></div>
                <p><b>11	DESCRIPTION</b></p>
                <p>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. Nirmatrelvir is a SARS-CoV-2 main protease (M<sup>pro</sup>) inhibitor, and ritonavir is an HIV-1 protease inhibitor and CYP3A inhibitor.</p>
                <p><u>Nirmatrelvir</u></p>
                <p>The chemical name of active ingredient of nirmatrelvir is (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide]. It has a molecular formula of C<sub>23</sub>H<sub>32</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> and a molecular weight of 499.54. Nirmatrelvir has the following structural formula:</p>
                <p>
                  <img src="#image1"
									 alt="Figure 1"
									 style="width:1.78937in;height:1.78937in"/>
                </p>
                <p>Nirmatrelvir is available as immediate-release, film-coated tablets. Each tablet contains 150 mg nirmatrelvir with the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate. The following are the ingredients in the film coating: hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol, and titanium dioxide.</p>
                <p><u>Ritonavir</u></p>
                <p>Ritonavir is chemically designated as 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1¬ methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12- tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub>, and its molecular weight is 720.95. Ritonavir has the following structural formula:</p>
                <p>
                  <img src="#image2"
									 alt="Figure 2"
									 style="width:5.78937in;height:1.78937in"/>
                </p>
                <p>Ritonavir is available as film-coated tablets. Each tablet contains 100 mg ritonavir with the following inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate. The film coating may include the following ingredients: colloidal anhydrous silica, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, polyethylene glycol, polysorbate 80, talc, and titanium dioxide.</p>
             </div>
            </text>
          </section>
          <section>
            <title value="12	CLINICAL PHARMACOLOGY"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34090-1"/>
                <display value="CLINICAL PHARMACOLOGY SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <div id="section6"></div>
              <p><b>12	CLINICAL PHARMACOLOGY</b></p>
              </div>
              </text>
          </section>
          <section>
            <title value="12.1	Mechanism of Action"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="43679-0"/>
                <display value="MECHANISM OF ACTION SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>12.1	Mechanism of Action</b></p>
              <p>Nirmatrelvir is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug [see <a href="#section12">Microbiology (12.4) </a>].</p>
              <p>Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 M<sup>pro</sup>. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.</p>
            </div>
              </text>
          </section>
          <section>
            <title value="12.2	Pharmacodynamics"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="43681-6"/>
                <display value="PHARMACODYNAMICS SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>12.2	Pharmacodynamics</b></p>
              <p><u>Cardiac Electrophysiology</u></p>
              <p>At 3 times the steady state peak plasma concentration (C<sub>max</sub>) at the recommended dose, nirmatrelvir does not prolong the QTc interval to any clinically relevant extent.</p>
            </div>
          </text>
          </section>
          <section>
            <title value="12.3	Pharmacokinetics"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="43682-4"/>
                <display value="PHARMACOKINETICS SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              <p><b>12.3	Pharmacokinetics</b></p>
              <p>The pharmacokinetics of nirmatrelvir/ritonavir were similar in healthy subjects and in subjects with mild to moderate COVID-19.</p>
              <p>Nirmatrelvir AUC increased in a less than dose proportional manner over a single dose range from 250 mg to 750 mg (0.83 to 2.5 times the approved recommended dose) and multiple dose range from 75 mg to 500 mg (0.25 to 1.67 times the approved recommended dose), when administered in combination with 100 mg ritonavir. Nirmatrelvir steady state was achieved on Day 2 following administration of the approved recommended dosage and the mean accumulation ratio was approximately 2-fold.</p>
              <p>The pharmacokinetic properties of nirmatrelvir/ritonavir are displayed in Table 2.</p>
              <body>
                <h5>Table 2:	Pharmacokinetic Properties of Nirmatrelvir and Ritonavir in Healthy Subjects</h5>
                <table ID="_Reftable3" border="1" width="75%">
                           <col width="31%"/>
                           <col width="28%"/>
                           <col width="28%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <content styleCode="bold">Nirmatrelvir (When Given With Ritonavir)</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Toprule " valign="bottom">
                                    <content styleCode="bold">Ritonavir</content>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                  <p>Abbreviations: CL/F=apparent clearance; hr=hour; L/hr=liters per hour; T<sub>½</sub>=terminal elimination half-life; T<sub>max</sub>=the time to reach C<sub>max</sub>; V<sub>z</sub>/F=apparent volume of distribution.</p>
                                  <p><sup>a</sup>.	Represents data after a single dose of 300 mg nirmatrelvir (2 x 150 mg tablet formulation) administered together with 100 mg ritonavir tablet in healthy subjects.</p>
                                  <p><sup>b</sup>.	Following a single oral dose of nirmatrelvir 300 mg boosted ritonavir 100 mg at -12 hours, 0 hours and 12 hours, administered under fed (high fat and high calorie meal) or fasted conditions.</p>
                                  <p><sup>c</sup>.	300 mg nirmatrelvir (oral suspension formulation) co-administered with 100 mg ritonavir (tablet formulation) twice daily for 3 days.</p>
                                  <p><sup>d</sup>.	Red blood cell to plasma ratio.</p>
                                  <p><sup>e</sup>.	Determined by <sup>19</sup>F-NMR analysis following 300 mg nirmatrelvir oral suspension administered at 0 hr enhanced with 100 mg ritonavir at  12 hours, 0 hours, 12 hours, and 24 hours.</p>
                                  <p><sup>f</sup>.	Determined by <sup>14</sup>C analysis following 600 mg <sup>14</sup>C-ritonavir oral solution (6 times the approved ritonavir dose).</p>
                                </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Absorption</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  T<sub>max</sub> (hr), median</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>3.00 <sup>a</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>3.98 <sup>a</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  Food effect</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Test/reference (fed/fasted) ratios of adjusted geometric means (90% CI) AUC<sub>inf</sub> and C<sub>max</sub> for nirmatrelvir were 119.67 (108.75, 131.68) 
                                      and 161.01 (139.05, 186.44), respectively. <sup>b</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Distribution</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  % bound to human plasma proteins</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>69%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>98–99%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  Blood-to-plasma ratio</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>0.60</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>0.14 <sup>d</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  V<sub>z</sub>/F (L), mean</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>104.7<sup>c</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>112.4<sup>c</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Elimination</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  Major route of elimination</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Renal elimination<sup>d</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Hepatic metabolism</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  Half-life (T<sub>½</sub>) (hr), mean</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>6.05<sup>a</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>6.15<sup>a</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  Oral clearance (CL/F) (L/hr), mean</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>8.99 <sup>c</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>13.92 <sup>c</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Metabolism</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  Metabolic pathways</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir is a CYP3A substrate but when dosed with ritonavir, metabolic clearance is minimal.</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Major CYP3A, Minor CYP2D6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Excretion</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  % drug-related material in feces</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>35.3% <sup>e</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>86.4% <sup>f</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  % of dose excreted as total (unchanged drug) in feces</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>27.5% <sup>e</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>33.8% <sup>f</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  % drug-related material in urine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>49.6% <sup>e</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>11.3% <sup>f</sup></paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>  % of dose excreted as total (unchanged drug) in urine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>55.0% <sup>e</sup></paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>3.5% <sup>f</sup></paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                      </body> 
                        <p>The predicted Day 5 nirmatrelvir exposure parameters in adult subjects with mild to moderate COVID-19 who were treated with PAXLOVID in EPIC-HR are presented in Table 3.</p>
                      <p></p>
                      <body>
                        <h5>Table 3:	Predicted Day 5 Nirmatrelvir Exposure Parameters Following Administration of Nirmatrelvir/Ritonavir 300 mg/100 mg Twice Daily in Subjects with Mild-to-Moderate COVID-19</h5>
                        <table ID="_Reftable4" border="1" width="75%">
                          <col width="36%"/>
                          <col width="51%"/>
                          <thead>
                             <tr>
                                <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                   <content styleCode="bold">Pharmacokinetic Parameter (units)<sup>a</sup></content>
                                 </th>
                                <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                   <content styleCode="bold">Nirmatrelvir<sup>b</sup></content>
                                </th>
                             </tr>
                          </thead>
                          <tfoot>
                             <tr>
                                <td align="left" colspan="2" valign="top">
                                 <P>Abbreviations: C<sub>max</sub>=predicted maximal concentration; C<sub>min</sub>=predicted minimal concentration (C<sub>trough</sub>).</P>
                                 <p><sup>a</sup>.	Data presented as geometric mean (10<sup>th</sup> and 90<sup>th</sup> percentile).</p>
                                 <p><sup>b</sup>.	Based on 1,016 subjects with their post hoc PK parameters.</p>
                                 <p><sup>c</sup>.	AUC<sub>tau</sub>=predicted area under the plasma concentration-time profile from time 0 to 12 hours for twice-daily dosing.</p>
                                </td>
                             </tr>
                          </tfoot>
                          <tbody>
                             <tr>
                                <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                   <paragraph>C<sub>max</sub> (µg/mL)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>3.43 (2.59, 4.52)</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Lrule Botrule " valign="top">
                                   <paragraph>AUC<sub>tau</sub> (µg*hr/mL)<sup>c</sup></paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>30.4 (22.9, 39.8)</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Botrule Lrule " valign="top">
                                   <paragraph>C<sub>min</sub> (µg/mL)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>1.57 (1.16, 2.10)</paragraph>
                                </td>
                             </tr>
                          </tbody>
                       </table>
                      </body>
                      <p><i>Effect of Food</i></p>
                      <p>No clinically significant differences in the pharmacokinetics of nirmatrelvir were observed following administration of a high fat meal (800-1000 calories; 50% fat) to healthy subjects.</p>
                      <p><u>Specific Populations</u></p>
                      <p>There were no clinically significant differences in the pharmacokinetics of nirmatrelvir based on age (18 to 86 years), sex, or race/ethnicity.</p>
                      <p><i>Pediatric Patients</i></p>
                      <p>The pharmacokinetics of nirmatrelvir/ritonavir in patients less than 18 years of age have not been established.</p>
                      <p><i>Patients with Renal Impairment</i></p>
                      <p>The pharmacokinetics of nirmatrelvir in patients with renal impairment following administration of a single oral dose of nirmatrelvir 100 mg (0.33 times the approved recommended dose) co-administered with ritonavir 100 mg are presented in Table 4. Compared to healthy controls with no renal impairment, the C<sub>max</sub> and AUC of nirmatrelvir in patients with mild renal impairment was 30% and 24% higher, in patients with moderate renal impairment was 38% and 87% higher, and in patients with severe renal impairment was 48% and 204% higher, respectively.</p>
                      <body>
                        <h5>Table 4:	Impact of Renal Impairment on Nirmatrelvir/Ritonavir Pharmacokinetics</h5>
                        <table ID="_Reftable6" border="1" width="75%">
                          <col width="17%"/>
                          <col width="16%"/>
                          <col width="18%"/>
                          <col width="18%"/>
                          <col width="18%"/>
                          <thead>
                             <tr>
                                <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                   <content styleCode="bold">Normal Renal Function </content>
                                   <br/>
                                   <content styleCode="bold">(n=8)</content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                   <content styleCode="bold">Mild Renal Impairment </content>
                                   <br/>
                                   <content styleCode="bold">(n=8)</content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                   <content styleCode="bold">Moderate Renal Impairment </content>
                                   <br/>
                                   <content styleCode="bold">(n=8)</content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                   <content styleCode="bold">Severe Renal Impairment </content>
                                   <br/>
                                   <content styleCode="bold">(n=8)</content>
                                </th>
                             </tr>
                          </thead>
                          <tfoot>
                             <tr>
                                <td align="left" colspan="5" valign="top">Abbreviations: AUC<sub>inf</sub>=area under the plasma concentration-time profile from time zero extrapolated to infinite time; C<sub>max</sub>=the observed maximum concentration; CV=coefficient of variation; SD=standard deviation; T<sub>½</sub>=terminal elimination half-life; T<sub>max</sub>=the time to reach C<sub>max</sub>.<br/>Values are presented as geometric mean (geometric % CV) except median (range) for T<sub>max</sub> and arithmetic mean ± SD for T<sub>½</sub>.</td>
                             </tr>
                          </tfoot>
                          <tbody>
                             <tr>
                                <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                   <paragraph>C<sub>max</sub> (µg/mL)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>1.60 (31)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>2.08 (29)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>2.21 (17)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>2.37 (38)</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Lrule Botrule " valign="top">
                                   <paragraph>AUC<sub>inf</sub> (µg*hr/mL)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>14.46 (20)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>17.91 (30)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>27.11 (27)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>44.04 (33)</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Lrule Botrule " valign="top">
                                   <paragraph>T<sub>max</sub> (hr)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>2.0 (1.0 – 4.0)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>2.0 (1.0 – 3.0)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>2.50 (1.0 – 6.0)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>3.0 (1.0 – 6.1)</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Botrule Lrule " valign="top">
                                   <paragraph>T<sub>½</sub> (hr)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>7.73 ± 1.82</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>6.60 ± 1.53</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>9.95 ± 3.42</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>13.37 ± 3.32</paragraph>
                                </td>
                             </tr>
                          </tbody>
                       </table>
                      </body>
                      <p><i>Patients with Hepatic Impairment</i></p>
                      <p>The pharmacokinetics of nirmatrelvir were similar in patients with moderate (Child-Pugh Class B) hepatic impairment compared to healthy subjects following administration of a single oral dose of nirmatrelvir 100 mg (0.33 times the approved recommended dose) co-administered with ritonavir 100 mg. The impact of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of nirmatrelvir or ritonavir has not been studied.</p>
                      <p><u>Clinical Drug Interaction Studies</u></p>
                      <p>Table 5 describes the effect of other drugs on the C<sub>max</sub> and AUC of nirmatrelvir.</p>
                      <body>
                        <h5>Table 5:	The Effect of Other Drugs on the Pharmacokinetic Parameters of Nirmatrelvir</h5>
                        <table border="1" width="95%">
                          <col width="18%"/>
                          <col width="18%"/>
                          <col width="18%"/>
                          <col width="12%"/>
                          <col width="17%"/>
                          <col width="17%"/>
                          <thead>
                             <tr>
                                <th align="center" rowspan="2" styleCode="Rrule Lrule Toprule " valign="bottom">
                                   <content styleCode="bold">Co-administered Drug</content>
                                </th>
                                <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="bottom">
                                   <content styleCode="bold">Dose (Schedule)</content>
                                </th>
                                <th align="center" rowspan="2" styleCode="Rrule Toprule " valign="bottom">
                                   <content styleCode="bold">N</content>
                                </th>
                                <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="bottom">
                                   <content styleCode="bold">Percent Ratio (in combination with co-administered drug/alone) of Nirmatrelvir Pharmacokinetic Parameters (90% CI); </content>
                                   <br/>
                                   <content styleCode="bold">No Effect=100</content>
                                </th>
                             </tr>
                             <tr>
                                <th align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                   <content styleCode="bold">Co-administered Drug</content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                   <content styleCode="bold">Nirmatrelvir/ Ritonavir</content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                   <content styleCode="bold">C<sub>max</sub>
                                   </content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                   <content styleCode="bold">AUC<sup>a</sup></content></th>
                             </tr>
                          </thead>
                          <tfoot>
                             <tr>
                                <td align="left" colspan="6" valign="top">
                                  <p>Abbreviations: AUC=area under the plasma concentration-time curve; AUC<sub>inf</sub>=area under the plasma concentration-time profile from time zero extrapolated to infinite time; AUC<sub>tau</sub>=area under the plasma concentration-time profile from time zero to time tau (τ), the dosing interval. CI=confidence interval; C<sub>max</sub>=observed maximum plasma concentrations.</p>
                                  <p>a.	For carbamazepine, AUC=AUC<sub>inf</sub>; for itraconazole, AUC=AUC<sub>tau</sub>.</p>
                                  <p>b.	Carbamazepine titrated up to 300 mg twice daily on Day 8 through Day 15 (e.g., 100 mg twice daily on Day 1 through Day 3 and 200 mg twice daily on Day 4 through Day 7).</p>
                                </td>
                             </tr>
                          </tfoot>
                          <tbody>
                             <tr>
                                <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                   <paragraph>Carbamazepine<sup>b</sup></paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>300 mg twice daily <br/>(16 doses)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>300 mg/100 mg once daily<br/>(2 doses)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>10</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>56.82<br/>(47.04, 68.62)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>44.50<br/>(33.77, 58.65)</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Botrule Lrule " valign="top">
                                   <paragraph>Itraconazole</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>200 mg once daily <br/>(8 doses)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>300 mg/100 mg twice daily<br/>(5 doses)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>11</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>118.57<br/>(112.50, 124.97)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>138.82<br/>(129.25, 149.11)</paragraph>
                                </td>
                             </tr>
                          </tbody>
                       </table>
                      </body>
                      <p>Table 6 describes the effect of nirmatrelvir/ritonavir on the C<sub>max</sub> and AUC of other drugs.</p>
                      <body>
                        <h5>Table 6:	Effect of Nirmatrelvir/Ritonavir on Pharmacokinetics of Other Drugs</h5>
                        <table border="1" width="95%">
                          <col width="18%"/>
                          <col width="18%"/>
                          <col width="18%"/>
                          <col width="12%"/>
                          <col width="17%"/>
                          <col width="17%"/>
                          <thead>
                             <tr>
                                <th align="center" rowspan="2" styleCode="Rrule Lrule Toprule " valign="bottom">
                                   <content styleCode="bold">Co-administered Drug</content>
                                </th>
                                <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="bottom">
                                   <content styleCode="bold">Dose (Schedule)</content>
                                </th>
                                <th align="center" rowspan="2" styleCode="Rrule Toprule " valign="bottom">
                                   <content styleCode="bold">N</content>
                                </th>
                                <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="bottom">
                                   <content styleCode="bold">Percent Ratio of Test/Reference of Geometric Means (90% CI);</content>
                                   <br/>
                                   <content styleCode="bold">No Effect=100</content>
                                </th>
                             </tr>
                             <tr>
                                <th align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                   <content styleCode="bold">Co-administered Drug</content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                   <content styleCode="bold">Nirmatrelvir/ Ritonavir</content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                   <content styleCode="bold">C<sub>max</sub>
                                   </content>
                                </th>
                                <th align="center" styleCode="Rrule Botrule " valign="bottom">
                                   <content styleCode="bold">AUC<sup>a</sup></content>
                                  </th>
                             </tr>
                          </thead>
                          <tfoot>
                             <tr>
                                <td align="left" colspan="6" valign="top">
                                <p>Abbreviations: AUC=area under the plasma concentration-time curve; CI=confidence interval; C<sub>max</sub>=observed maximum plasma concentrations; P-gp=p-glycoprotein.</p>
                                <p>a.	AUC=AUC<sub>inf</sub> for both midazolam and dabigatran.</p>
                                <p>b.	For midazolam, Test=nirmatrelvir/ritonavir plus midazolam, Reference=Midazolam. Midazolam is an index substrate for CYP3A. For dabigatran, Test=nirmatrelvir/ritonavir plus dabigatran, Reference=Dabigatran. Dabigatran is an index substrate for P-gp.</p>
                                </td>
                             </tr>
                          </tfoot>
                          <tbody>
                             <tr>
                                <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                   <paragraph>Midazolam<sup>b</sup></paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>2 mg <br/>(1 dose)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>300 mg/100 mg twice daily<br/>(9 doses)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>10</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>368.33<br/>(318.91, 425.41)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                   <paragraph>1430.02<br/>(1204.54, 1697.71)</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Botrule Lrule " valign="top">
                                   <paragraph>Dabigatran<sup>b</sup></paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>75 mg <br/>(1 dose)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>300 mg/100 mg twice daily<br/>(4 doses)<sup>b</sup></paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>24</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>233.06<br/>(172.14, 315.54)</paragraph>
                                </td>
                                <td align="center" styleCode="Rrule Botrule " valign="top">
                                   <paragraph>194.47<br/>(155.29, 243.55)</paragraph>
                                </td>
                             </tr>
                          </tbody>
                       </table>
                      </body>
                      <p></p>
                      <p><i>In Vitro Studies</i></p>
                      <p><i>Cytochrome P450 (CYP) Enzymes:</i></p>
                      <lu>
                        <li>Nirmatrelvir is a reversible and time dependent inhibitor of CYP3A, but not an inhibitor CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. Nirmatrelvir is an inducer of CYP2B6, 2C8, 2C9, and 3A4, but there is minimal risk for pharmacokinetic interactions arising from induction of these CYP enzymes at the proposed therapeutic dose.</li>
                        <li>Ritonavir is a substrate of CYP2D6 and CYP3A. Ritonavir is an inducer of CYP1A2, CYP2C9, CYP2C19, CYP2B6, and CYP3A.</li>
                      </lu>
                      <p><i>Transporter Systems:</i>Nirmatrelvir is an inhibitor of P-gp and OATP1B1. Nirmatrelvir is a substrate for P-gp, but not BCRP, MATE1, MATE2K, NTCP, OAT1, OAT2, OAT3, OCT1, OCT2, PEPT1, OATP1B1, OATP1B3, OATP2B1, or OATP4C1.</p>
                    </div>
                    </text>
                  </section>
                      <section>
                        <title value="12.4	Microbiology"/>
                        <code>
                          <coding>
                            <system value="2.16.840.1.113883.6.1"/>
                            <code value="49489-8"/>
                            <display value="MICROBIOLOGY SECTION"/>
                          </coding>
                        </code>
                        <text>
                          <status value="generated"/>
                          <div xmlns="http://www.w3.org/1999/xhtml">
                          <p><b>12.4	Microbiology</b></p>
                          <p><u>Mechanism of Action</u></p>
                          <p>Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (M<sup>pro</sup>), also referred to as 3C-like protease (3CL<sup>pro</sup>) or nonstructural protein 5 (nsp5) protease. Inhibition of SARS-CoV-2 M<sup>pro</sup> renders it incapable of processing the viral polyproteins pp1a and pp1ab, preventing viral replication. Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 M<sup>pro</sup> in a biochemical assay with a K<sub>i</sub> value of 3.1 nM and an IC<sub>50</sub> value of 19.2 nM. Nirmatrelvir was found to bind directly to the SARS-CoV-2 M<sup>pro</sup> active site by X-ray crystallography.</p>
                          <p><u>Antiviral Activity</u></p>
                          <p><i>Cell Culture Antiviral Activity</i></p>
                          <p>Nirmatrelvir exhibited antiviral activity against SARS-CoV-2 (USA-WA1/2020 isolate) infection of differentiated normal human bronchial epithelial (dNHBE) cells with EC<sub>50</sub> and EC<sub>90</sub> values of 62 nM (31 ng/mL) and 181 nM (90 ng/mL), respectively, after 3 days of drug exposure.</p>
                          <p>The antiviral activity of nirmatrelvir against the Omicron sub-variants BA.2, BA.2.12.1, BA.4, BA.4.6, BA.5, BF.7, BQ.1, BQ.1.11, and XBB.1.5 was assessed in Vero E6-TMPRSS2 cells in the presence of a P-gp inhibitor. Nirmatrelvir had a median EC<sub>50</sub> value of 83 nM (range: 39-146 nM) against the Omicron sub-variants, reflecting EC<sub>50</sub> value fold-changes &#8804;1.5 relative to the USA-WA1/2020 isolate.</p>
                          <p>In addition, the antiviral activity of nirmatrelvir against the SARS-CoV-2 Alpha, Beta, Gamma, Delta, Lambda, Mu, and Omicron BA.1 variants was assessed in Vero E6 P-gp knockout cells. Nirmatrelvir had a median EC<sub>50</sub> value of 25 nM (range: 16-141 nM). The Beta variant was the least susceptible variant tested, with an EC<sub>50</sub> value fold-change of 3.7 relative to USA WA1/2020. The other variants had EC<sub>50</sub> value fold-changes &#8804;1.1 relative to USA-WA1/2020.</p>
                          <p><i>Clinical Antiviral Activity</i></p>
                          <p>In clinical trial EPIC-HR, which enrolled subjects who were primarily infected with the SARS-CoV-2 Delta variant, PAXLOVID treatment was associated with a 0.83 log<sub>50</sub> copies/mL greater median decline in viral RNA shedding levels in nasopharyngeal samples through Day 5 (mITT1 analysis set, all treated subjects with onset of symptoms &#8804;5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment); similar results were observed in the mITT2 analysis set (all treated subjects with onset of symptoms &#8804;5 days). In the EPIC-SR trial, which included subjects who were infected with SARS-CoV-2 Delta (79%) or Omicron (19%) variants, PAXLOVID treatment was associated with a 1.05 log<sub>10</sub> copies/mL greater median decline in viral RNA shedding levels in nasopharyngeal samples through Day 5, with similar declines observed in subjects infected with Delta or Omicron variants. The degree of reduction in viral RNA levels relative to placebo following 5 days of PAXLOVID treatment was similar between unvaccinated high-risk subjects in EPIC-HR and vaccinated high-risk subjects in EPIC-SR.</p>
                          <p><u>Antiviral Resistance</u></p>
                          <p><i>In Cell Culture and Biochemical Assays</i></p>
                          <p>SARS-CoV-2 M <sup>pro</sup> residues potentially associated with nirmatrelvir resistance have been identified using a variety of methods, including SARS-CoV-2 resistance selection, testing of recombinant SARS-CoV-2 viruses with M <sup>pro</sup> substitutions, and biochemical assays with recombinant SARS-CoV-2 M <sup>pro</sup> containing amino acid substitutions. Table 7 indicates M <sup>pro</sup> substitutions and combinations of M <sup>pro</sup> substitutions that have been observed in nirmatrelvir-selected SARS-CoV-2 in cell culture. Individual M <sup>pro</sup> substitutions are listed regardless of whether they occurred alone or in combination with other Mpro substitutions. Note that the M <sup>pro</sup> S301P and T304I substitutions overlap the P6 and P3 positions of the nsp5/nsp6 cleavage site located at the C-terminus of M <sup>pro</sup>. Substitutions at other M <sup>pro</sup> cleavage sites have not been associated with nirmatrelvir resistance in cell culture. The clinical significance of these substitutions is unknown.</p>
                      <body>
                        <h5>Table 7:	SARS-CoV-2 M <sup>pro</sup> Amino Acid Substitutions Selected by Nirmatrelvir in Cell Culture</h5>
                        <table border="1" width="100%">
                          <col width="29%"/>
                          <col width="71%"/>
                          <tfoot>
                             <tr>
                                <td align="left" colspan="2" valign="top">Abbreviation: ND=no data.</td>
                             </tr>
                          </tfoot>
                          <tbody>
                             <tr>
                                <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                   <paragraph>Single Substitutions</paragraph>
                                   <paragraph>(EC<sub>50</sub> value fold change)</paragraph>
                                </td>
                                <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                   <paragraph>T21I (1.1-4.6), L50F (1.5-4.2), P108S (ND), T135I (ND), F140L (4.1), S144A (2.2-5.3), C160F (ND), E166A (3.3), E166V (25‑288), L167F (ND), T169I (ND), H172Y (ND), A173V (0.9-1.7), V186A (ND), R188G (ND), A191V (ND), A193P (ND), P252L (5.9), S301P (ND), and T304I (1.4-5.5).</paragraph>
                                </td>
                             </tr>
                             <tr>
                                <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                   <paragraph>≥2 Substitutions</paragraph>
                                   <paragraph>(EC<sub>50</sub> value fold change)</paragraph>
                                </td>
                                <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                   <paragraph>T21I+S144A (9.4), T21I+E166V (83), T21I+A173V (3.1), T21I+T304I (3.0-7.9), L50F+E166V (34-175), L50F+T304I (5.9), T135I+T304I (3.8), F140L+A173V (10.1), H172Y+P252L (ND), A173V+T304I (20.2), T21I+L50F+A193P+S301P (28.8), T21I+S144A+T304I (27.8), T21I+C160F+A173V+V186A+T304I (28.5), T21I+A173V+T304I (15), and L50F+F140L+L167F+T304I (54.7).</paragraph>
                                </td>
                             </tr>
                          </tbody>
                       </table>
                      </body>
                    <p>In a biochemical assay using recombinant SARS-CoV-2 M<sup>pro</sup> containing amino acid substitutions, the following SARS-CoV-2 M<sup>pro</sup> substitutions led to &#8806;3-fold reduced nirmatrelvir activity (fold-change based on K<sub>i</sub> values): Y54A (25), F140A (21), F140L (7.6), F140S (260), G143S (3.6), S144A (46), S144E (480), S144T (170), H164N (6.7), E166A (35), E166G (6.2), E166V (7,700), H172Y (250), A173S (4.1), A173V (16), R188G (38), Q192L (29), Q192P (7.8), and V297A (3.0). In addition, the following combinations of M<sup>pro</sup> substitutions led to &#8806;3-fold reduced nirmatrelvir activity: T21I+S144A (20), T21I+E166V (11,000), T21I+A173V (15), L50F+E166V (4,500), T135I+T304I (5.1), F140L+A173V (95), H172Y+P252L (180), A173V+T304I (28), T21I+S144A+T304I (51), T21I+A173V+T304I (55), L50F+E166A+L167F (210), T21I+L50F+A193P+S301P (7.3), L50F+F140L+L167F+T304I (190), and T21I+C160F+A173V+V186A+T304I (28). The following substitutions and substitution combinations emerged in cell culture but conferred &lt;3-fold reduced nirmatrelvir activity in biochemical assays: T21I (1.6), L50F (0.2), P108S (2.9), T135I (2.2), C160F (0.6), L167F (0.9), T169I (1.4), V186A (0.8), A191V (0.8), A193P (0.9), P252L (0.9), S301P (0.2), T304I (1.0), T21I+T304I (1.8), and L50F+T304I (1.3). The clinical significance of these substitutions is unknown.</p>
                    <p><i>In Clinical Trials</i></p>
                    <p>Treatment-emergent substitutions were evaluated among subjects in clinical trials EPIC-HR/SR with sequence data available at both baseline and a post-baseline visit (n=907 PAXLOVID-treated subjects, n=946 placebo treated subjects). SARS CoV 2 M<sup>pro</sup> amino acid changes were classified as PAXLOVID treatment emergent substitutions if they occurred at the same amino acid position in 3 or more PAXLOVID treated subjects and were ≥2.5-fold more common in PAXLOVID-treated subjects than placebo treated subjects. The following PAXLOVID treatment-emergent M<sup>pro</sup> substitutions were observed: T98I/R/del(n=4), E166V (n=3), and W207L/R/del (n=4). Within the M<sup>pro</sup> cleavage sites, the following PAXLOVID treatment-emergent substitutions were observed: A5328S/V(n=7) and S6799A/P/Y (n=4). These cleavage site substitutions were not associated with the co-occurrence of any specific M<sup>pro</sup> substitutions.</p>
                    <p>None of the treatment-emergent substitutions listed above in M<sup>pro</sup> or M<sup>pro</sup> cleavage sites occurred in PAXLOVID-treated subjects who experienced hospitalization. Thus, the clinical significance of these substitutions is unknown.</p>
                    <p><u>Viral RNA Rebound (With and Without COVID-19 Symptoms) and Treatment-Emergent Substitutions</u></p>
                    <p>EPIC-HR and EPIC-SR were not designed to evaluate COVID-19 rebound; exploratory analyses were conducted to assess the relationship between PAXLOVID use and rebound in viral RNA shedding levels or self-reported COVID-19 symptoms.</p>
                    <p>Post-treatment increases in SARS-CoV-2 RNA shedding levels in nasopharyngeal samples were observed on Day 10 and/or Day 14 in a subset of PAXLOVID and placebo recipients in EPIC HR and EPIC-SR, irrespective of COVID-19 symptoms. The frequency of detection of post-treatment viral RNA rebound varied according to analysis parameters, but was generally similar among PAXLOVID and placebo recipients. A similar or smaller percentage of placebo recipients compared to PAXLOVID recipients had nasopharyngeal viral RNA results &lt;lower limit of quantitation (LLOQ) at all study timepoints in both the treatment and post-treatment periods.</p>
                    <p>In EPIC-HR, of 59 PAXLOVID-treated subjects identified with post-treatment viral RNA rebound and with available viral sequence data, treatment-emergent substitutions in M<sup>pro</sup> potentially reducing nirmatrelvir activity were detected in 2 (3%) subjects, including E166V in 1 subject and T304I in 1 subject. Both subjects had viral RNA shedding levels &lt;LLOQ by Day 14.</p>
                    <p>Post-treatment viral RNA rebound was not associated with the primary clinical outcome of COVID-19 related hospitalization or death from any cause through Day 28 following the single 5-day course of PAXLOVID treatment. The clinical relevance of post-treatment increases in viral RNA following PAXLOVID or placebo treatment is unknown.</p>
                    <p>The frequency of symptom rebound through Day 28, irrespective of viral RNA results, was similar among PAXLOVID and placebo recipients. The frequency of combined viral RNA rebound plus symptom rebound could not be fully assessed as most episodes of symptom rebound occurred after Day 14 (the last day SARS CoV 2 RNA levels were routinely assessed).</p>
                    <p><u>Cross-Resistance</u></p>
                    <p>Cross-resistance is not expected between nirmatrelvir and remdesivir or any other anti-SARS-CoV-2 agents with different mechanisms of action (i.e., agents that are not M <sup>pro</sup> inhibitors).</p>
                  </div>
                </text>
              </section>
              <section>
            <title value="13	NONCLINICAL TOXICOLOGY"/>
            <code>
              <coding>
                <system value="2.16.840.1.113883.6.1"/>
                <code value="34084-4"/>
                <display value="ADVERSE REACTIONS SECTION"/>
              </coding>
            </code>
            <text>
              <status value="generated"/>
              <div xmlns="http://www.w3.org/1999/xhtml">
              </div>
              </text>
          </section>
        </section>
      </Composition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:7ac0d617-838e-4ae0-ad3c-c3be9004e921"/>
    <resource>
      <Organization>
        <id value="7ac0d617-838e-4ae0-ad3c-c3be9004e921"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="7ac0d617-838e-4ae0-ad3c-c3be9004e921"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="1.3.6.1.4.1.519.1"/>
            <code value="113480771"/>
            <display value="REGISTRANT"/>
          </coding>
        </type>
        <name value="Pfizer Inc"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="466 Hudson Boulevard East, New York, NY 10001, United States"/>
            <line value="466 Hudson Boulevard East, New York, NY 10001"/>
            <city value="New York"/>
            <country value="US"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:a7ea98b8-b6b5-48a2-bdbf-944593efe4b8"/>
    <resource>
      <Organization>
        <id value="a7ea98b8-b6b5-48a2-bdbf-944593efe4b8"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="a7ea98b8-b6b5-48a2-bdbf-944593efe4b8"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="1.3.6.1.4.1.519.1"/>
            <code value="134489525"/>
            <display value="LABELER"/>
          </coding>
        </type>
        <name value="Pfizer Laboratories Div Pfizer Inc"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="466 Hudson Boulevard East, New York, NY 10001, United States"/>
            <line value="466 Hudson Boulevard East, New York, NY 10001"/>
            <city value="New York"/>
            <country value="US"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:98000f5e-794c-497a-ba3c-fe5b43a5b5ff"/>
    <resource>
      <Organization>
        <id value="98000f5e-794c-497a-ba3c-fe5b43a5b5ff"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="98000f5e-794c-497a-ba3c-fe5b43a5b5ff"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C43360"/>
            <display value="MANUFACTURE"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84731"/>
            <display value="PACK"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84732"/>
            <display value="LABEL"/>
          </coding>
        </type>
        <name value="Pfizer Manufacturing Deutschland GmbH"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Mooswaldallee 1, Bruehl, Freiburg Im Breisgau, Baden-Wuerttemberg, 79108, Germany"/>
            <line value="Mooswaldallee 1, Bruehl, Freiburg Im Breisgau, Baden-Wuerttemberg"/>
            <city value="Freiburg Im Breisgau"/>
            <country value="DE"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:42cee25b-621c-463a-ad10-d4d4d8794715"/>
    <resource>
      <Organization>
        <id value="42cee25b-621c-463a-ad10-d4d4d8794715"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="42cee25b-621c-463a-ad10-d4d4d8794715"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C43360"/>
            <display value="MANUFACTURE"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84731"/>
            <display value="PACK"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84732"/>
            <display value="LABEL"/>
          </coding>
        </type>
        <name value="Pfizer Italia S.r.L"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Localita Marino Del Tronto, Ascoli Piceno, AP, 63100, Italy"/>
            <line value="Localita Marino Del Tronto"/>
            <city value="Ascoli Piceno"/>
            <country value="IT"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:f480bbb0-5cfe-4de6-b548-91531eb6808c"/>
    <resource>
      <Organization>
        <id value="f480bbb0-5cfe-4de6-b548-91531eb6808c"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="f480bbb0-5cfe-4de6-b548-91531eb6808c"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C43360"/>
            <display value="MANUFACTURE"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84731"/>
            <display value="PACK"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84732"/>
            <display value="LABEL"/>
          </coding>
        </type>
        <name value="Pfizer Ireland Pharmaceuticals"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Ballintaggart, Ringaskiddy, Co. Cork, Irlande"/>
            <line value="Ballintaggart, Ringaskiddy"/>
            <city value="Co. Cork"/>
            <country value="IE"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:7efca7ec-59f0-4593-83ab-ce3d8d9fb3cd"/>
    <resource>
      <Organization>
        <id value="7efca7ec-59f0-4593-83ab-ce3d8d9fb3cd"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="7efca7ec-59f0-4593-83ab-ce3d8d9fb3cd"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84731"/>
            <display value="PACK"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84732"/>
            <display value="LABEL"/>
          </coding>
        </type>
        <name value="AndersonBrecon Inc."/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="4545 Assembly Drive - Rockford IL 61109, United States"/>
            <line value="4545 Assembly Drive - Rockford"/>
            <city value="Illinois"/>
            <country value="US"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:d9430d8a-0298-4260-985e-2c6cf0890152"/>
    <resource>
      <Organization>
        <id value="d9430d8a-0298-4260-985e-2c6cf0890152"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="d9430d8a-0298-4260-985e-2c6cf0890152"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84731"/>
            <display value="PACK"/>
          </coding>
          <coding>
            <system value="2.16.840.1.113883.3.26.1.1"/>
            <code value="C84732"/>
            <display value="LABEL"/>
          </coding>
        </type>
        <name value="Sharp Packaging Services, LLC"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Building 1, 7451 Keebler Way Allentown, PA 18106, United States"/>
            <line value="Building 1, 7451 Keebler Way Allentown"/>
            <city value="Pennsylvania"/>
            <country value="US"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:446915fa-e64e-45cb-8a98-ddd47a53193b"/>
    <resource>
      <MedicinalProductDefinition>
        <id value="446915fa-e64e-45cb-8a98-ddd47a53193b"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <system value="https://www.fda.gov/"/>
          <value value="446915fa-e64e-45cb-8a98-ddd47a53193b"/>
        </identifier>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-type"/>
            <code value="MedicinalProduct"/>
            <display value="Medicinal Product"/>
          </coding>
        </type>
        <domain>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-domain"/>
            <code value="Human"/>
            <display value="Human use"/>
          </coding>
        </domain>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="Active"/>
          </coding>
        </status>
        <statusDate value="2023-05-01T00:00:00Z"/>
        <legalStatusOfSupply>
          <coding>
            <system value="http://hl7.org/fhir/legal-status-of-supply"/>
            <code value="100000072084"/>
            <display value="Medicinal product subject to medical prescription"/>
          </coding>
        </legalStatusOfSupply>
        <classification>
					<coding>
						<system value="http://hl7.org/fhir/ValueSet/medicinal-product-classification"/>
						<code value="J05AE30"/>
						<display value="antivirals protease inhibitors"/>
					</coding>
				</classification>
        <route>
					<coding>
						<system value="http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/routeOfAdministration"/>
						<code value="26643006"/>
						<display value="Oral route"/>
					</coding>
				</route>
        <name>
          <productName value="PAXLOVID 150 mg/100 mg film-coated tablets"/>
          <usage>
            <country>
              <coding>
                <system value="http://hl7.org/fhir/ValueSet/country"/>
                <code value="US"/>
                <display value="United States"/>
              </coding>
            </country>
            <jurisdiction>
              <coding>
                <system value="http://hl7.org/fhir/ValueSet/jurisdiction"/>
                <code value="US"/>
                <display value="United States"/>
              </coding>
            </jurisdiction>
            <language>
              <coding>
                <system value="http://hl7.org/fhir/ValueSet/all-languages"/>
                <code value="en"/>
                <display value="English"/>
              </coding>
            </language>
          </usage>
        </name>
      </MedicinalProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:7e65ad47-0f99-4bc2-a849-75887e19c6e9"/>
    <resource>
      <PackagedProductDefinition>
        <id value="7e65ad47-0f99-4bc2-a849-75887e19c6e9"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="594b9632-affb-4108-88ac-caad7541af00"/>
        </identifier>
        <name value="PAXLOVID 150 mg/100 mg film-coated tablets blister"/>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-type"/>
            <code value="MedicinalProduct"/>
            <display value="Medicinal Product"/>
          </coding>
        </type>
        <packageFor>
          <reference value="urn:uuid:446915fa-e64e-45cb-8a98-ddd47a53193b"/>
        </packageFor>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="Active"/>
          </coding>
        </status>
        <statusDate value="2023-05-01T00:00:00Z"/>
        <containedItemQuantity>
          <value value="150/100"/>
          <unit value="mg"/>
        </containedItemQuantity>
        <packaging>
          <identifier>
            <system value="https://www.fda.gov/"/>
            <value value="6e78d87c-8599-48a8-b7cb-3f45a6e0a294"/>
          </identifier>
          <type>
            <coding>
              <system value="http://hl7.org/fhir/medicinal-product-package-type"/>
              <code value="100000073496"/>
              <display value="Blister"/>
            </coding>
          </type>
          <quantity value="20"/>
          <material>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003210"/>
              <display value="Orientated PolyAmide"/>
            </coding>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003200"/>
              <display value="Aluminium"/>
            </coding>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003222"/>
              <display value="PolyVinyl Chloride"/>
            </coding>
          </material>
        </packaging>
        <packaging>
          <identifier>
            <system value="https://www.fda.gov/"/>
            <value value="158b120c-5c6d-4ed0-bf93-2284fc485853"/>
          </identifier>
          <type>
            <coding>
              <system value="http://hl7.org/fhir/medicinal-product-package-type"/>
              <code value="100000073496"/>
              <display value="Blister"/>
            </coding>
          </type>
          <quantity value="30"/>
          <material>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003210"/>
              <display value="Orientated PolyAmide"/>
            </coding>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003200"/>
              <display value="Aluminium"/>
            </coding>
            <coding>
              <system value="http://hl7.org/fhir/package-material"/>
              <code value="200000003222"/>
              <display value="PolyVinyl Chloride"/>
            </coding>
          </material>
        </packaging>
      </PackagedProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:eed1ccb4-cbdb-49ab-8d52-c4af3367f0f3"/>
    <resource>
      <AdministrableProductDefinition>
        <id value="eed1ccb4-cbdb-49ab-8d52-c4af3367f0f3"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <system value="https://www.who-umc.org/phpid"/>
          <value value="236b14ee-38bc-41ec-801a-b2c229a75e64"/>
        </identifier>
        <status value="active"/>
        <formOf>
          <reference value="urn:uuid:446915fa-e64e-45cb-8a98-ddd47a53193b"/>
        </formOf>
        <administrableDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/administrable-dose-form"/>
            <code value="100000073665"/>
            <display value="Film-coated tablet"/>
          </coding>
        </administrableDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="Tablet"/>
          </coding>
        </unitOfPresentation>
        <producedFrom>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </producedFrom>
        <routeOfAdministration>
          <code>
            <coding>
              <system value="http://snomed.info/sct"/>
              <code value="26643006"/>
              <display value="Oral route"/>
            </coding>
          </code>
        </routeOfAdministration>
      </AdministrableProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:391fe0c6-50cc-45df-86ef-e0ec7cf6ab7f"/>
    <resource>
      <AdministrableProductDefinition>
        <id value="391fe0c6-50cc-45df-86ef-e0ec7cf6ab7f"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"/>
        </meta>
        <identifier>
          <system value="https://www.who-umc.org/phpid"/>
          <value value="10f671c1-cec0-4d00-9dfe-316b76804b6c"/>
        </identifier>
        <status value="active"/>
        <formOf>
          <reference value="urn:uuid:446915fa-e64e-45cb-8a98-ddd47a53193b"/>
        </formOf>
        <administrableDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/administrable-dose-form"/>
            <code value="100000073665"/>
            <display value="Film-coated tablet"/>
          </coding>
        </administrableDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="Tablet"/>
          </coding>
        </unitOfPresentation>
        <producedFrom>
          <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </producedFrom>
        <routeOfAdministration>
          <code>
            <coding>
              <system value="http://snomed.info/sct"/>
              <code value="26643006"/>
              <display value="Oral route"/>
            </coding>
          </code>
        </routeOfAdministration>
      </AdministrableProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
    <resource>
      <ManufacturedItemDefinition>
        <id value="257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="473f236d-9d51-47e7-9e27-576be2c266a1"/>
        </identifier>
        <name value="Nirmatrelvir 150 mg Film-Coated Tablets"/>
        <status value="active"/>
        <manufacturedDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/manufactured-dose-form"/>
            <code value="100000073665"/>
            <display value="Film-coated tablet"/>
          </coding>
        </manufacturedDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="Tablet"/>
          </coding>
        </unitOfPresentation>
        <manufacturer>
          <reference value="urn:uuid:98000f5e-794c-497a-ba3c-fe5b43a5b5ff"/>
        </manufacturer> 
        <manufacturer>
          <reference value="urn:uuid:42cee25b-621c-463a-ad10-d4d4d8794715"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:f480bbb0-5cfe-4de6-b548-91531eb6808c"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:7efca7ec-59f0-4593-83ab-ce3d8d9fb3cd"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:d9430d8a-0298-4260-985e-2c6cf0890152"/>
        </manufacturer>
      </ManufacturedItemDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
    <resource>
      <ManufacturedItemDefinition>
        <id value="89209958-fbe0-43ef-8650-4acd7828dc16"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://www.fda.gov/"/>
          <value value="3ab80f4d-3932-47cd-89c6-c480006fd7cc"/>
        </identifier>
        <name value="Ritonavir 100 mg Film-Coated Tablets"/>
        <status value="active"/>
        <manufacturedDoseForm>
          <coding>
            <system value="http://hl7.org/fhir/manufactured-dose-form"/>
            <code value="100000073665"/>
            <display value="Film-coated tablet"/>
          </coding>
        </manufacturedDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="http://hl7.org/fhir/unit-of-presentation"/>
            <code value="200000002152"/>
            <display value="Tablet"/>
          </coding>
        </unitOfPresentation>
        <manufacturer>
          <reference value="urn:uuid:98000f5e-794c-497a-ba3c-fe5b43a5b5ff"/>
        </manufacturer> 
        <manufacturer>
          <reference value="urn:uuid:42cee25b-621c-463a-ad10-d4d4d8794715"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:f480bbb0-5cfe-4de6-b548-91531eb6808c"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:7efca7ec-59f0-4593-83ab-ce3d8d9fb3cd"/>
        </manufacturer>
        <manufacturer>
          <reference value="urn:uuid:d9430d8a-0298-4260-985e-2c6cf0890152"/>
        </manufacturer>
      </ManufacturedItemDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:586158ed-e0aa-4b5d-be22-124afbe607bf"/>
    <resource>
      <Ingredient>
        <id value="586158ed-e0aa-4b5d-be22-124afbe607bf"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7R9A5P7H32"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072072"/>
            <display value="Active"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7R9A5P7H32"/>
                <display value="Nirmatrelvir"/>
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="150"/>
              <unit value="mg"/>
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
                <code value="ACTI"/>
              </coding>
              <text value="active ingredient"/>
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:d1850914-f2e0-4c5c-b524-1379d144b9be"/>
    <resource>
      <Ingredient>
        <id value="d1850914-f2e0-4c5c-b524-1379d144b9be"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="O3J8G9O825"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072072"/>
            <display value="Active"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="O3J8G9O825"/>
                <display value="Ritonavir"/>
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="100"/>
              <unit value="mg"/>
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
                <code value="ACTI"/>
              </coding>
              <text value="active ingredient"/>
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:5376cdfb-4e45-4a03-82c1-fa7add93ce8f"/>
    <resource>
      <Ingredient>
        <id value="5376cdfb-4e45-4a03-82c1-fa7add93ce8f"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="ETJ7Z6XBU4"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="ETJ7Z6XBU4"/>
                <display value="Silicon dioxide, colloidal"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:a387eb05-5527-4829-8c5d-99f6cfc81607"/>
    <resource>
      <Ingredient>
        <id value="a387eb05-5527-4829-8c5d-99f6cfc81607"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="M28OL1HH48"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="M28OL1HH48"/>
                <display value="Croscarmellose sodium"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:1663439c-6fe1-4547-a961-c91515a5aab2"/>
    <resource>
      <Ingredient>
        <id value="1663439c-6fe1-4547-a961-c91515a5aab2"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="EWQ57Q8I5X"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="EWQ57Q8I5X"/>
                <display value="Lactose monohydrate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:fa1e316d-8ce4-460b-b1a4-3f433e81fe2e"/>
    <resource>
      <Ingredient>
        <id value="fa1e316d-8ce4-460b-b1a4-3f433e81fe2e"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="OP1R32D61U"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="OP1R32D61U"/>
                <display value="Microcrystalline cellulose"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:fa1e316d-8ce4-460b-b1a4-3f433e81fe2e"/>
    <resource>
      <Ingredient>
        <id value="fa1e316d-8ce4-460b-b1a4-3f433e81fe2e"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7CV7WJK4UI"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7CV7WJK4UI"/>
                <display value="Sodium stearyl fumarate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:c2f609c3-0050-40a8-9adf-af8ba16a99e6"/>
    <resource>
      <Ingredient>
        <id value="c2f609c3-0050-40a8-9adf-af8ba16a99e6"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="0HO1H52958"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="0HO1H52958"/>
                <display value="Hypromellose 2910 (10000 MPA.S)"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:3a67a2b7-6b88-43ab-9749-249949f4ee16"/>
    <resource>
      <Ingredient>
        <id value="3a67a2b7-6b88-43ab-9749-249949f4ee16"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="1K09F3G675"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="1K09F3G675"/>
                <display value="Iron oxide red"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:d8dc0e7c-9fe2-4d51-a2a4-a24c32e93652"/>
    <resource>
      <Ingredient>
        <id value="d8dc0e7c-9fe2-4d51-a2a4-a24c32e93652"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="3WJQ0SDW1A"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="3WJQ0SDW1A"/>
                <display value="Polyethylene glycol"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:cb1b797e-d611-4b3d-8730-4d157897e683"/>
    <resource>
      <Ingredient>
        <id value="cb1b797e-d611-4b3d-8730-4d157897e683"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="15FIX9V2JP"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:257b8ddd-aa19-4cff-934a-4084c3c5ee4c"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="15FIX9V2JP"/>
                <display value="Titanium Dioxide"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:209f5660-227d-4a03-9468-5ef3717acf78"/>
    <resource>
      <Ingredient>
        <id value="209f5660-227d-4a03-9468-5ef3717acf78"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="D9C330MD8B"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="D9C330MD8B"/>
                <display value="Copovidone"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:ddb5269b-92b6-4c0f-8298-f19639149c54"/>
    <resource>
      <Ingredient>
        <id value="ddb5269b-92b6-4c0f-8298-f19639149c54"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="6W9PS8B71J"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="6W9PS8B71J"/>
                <display value="Sorbitan laurate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:89be6703-7243-4504-b3a3-5b310964472d"/>
    <resource>
      <Ingredient>
        <id value="89be6703-7243-4504-b3a3-5b310964472d"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="ETJ7Z6XBU4"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="ETJ7Z6XBU4"/>
                <display value="Silica colloidal anhydrous"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:08710c3f-2daa-4aaf-a244-5069eda2c215"/>
    <resource>
      <Ingredient>
        <id value="08710c3f-2daa-4aaf-a244-5069eda2c215"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="L11K75P92J"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="L11K75P92J"/>
                <display value="Calcium hydrogen phosphate anhydrous"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:c53a54cd-ef20-4f0a-aacb-4adc8753a1e4"/>
    <resource>
      <Ingredient>
        <id value="c53a54cd-ef20-4f0a-aacb-4adc8753a1e4"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7CV7WJK4UI"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7CV7WJK4UI"/>
                <display value="Sodium stearyl fumarate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:c8747c25-3c3a-4536-94b2-cad65690fa3b"/>
    <resource>
      <Ingredient>
        <id value="c8747c25-3c3a-4536-94b2-cad65690fa3b"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="3NXW29V3WO"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="3NXW29V3WO"/>
                <display value="Hypromellose"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:89c2d118-65f8-40bb-ad83-8da2d17a0958"/>
    <resource>
      <Ingredient>
        <id value="89c2d118-65f8-40bb-ad83-8da2d17a0958"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="15FIX9V2JP"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="15FIX9V2JP"/>
                <display value="Titanium Dioxide"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:4e81997a-1ba4-4561-b894-8fe037a4196c"/>
    <resource>
      <Ingredient>
        <id value="4e81997a-1ba4-4561-b894-8fe037a4196c"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="G2M7P15E5P"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="G2M7P15E5P"/>
                <display value="Polyethylene Glycol 3350"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:44524cfe-9460-43b6-a2c1-8cc8fc89e33e"/>
    <resource>
      <Ingredient>
        <id value="44524cfe-9460-43b6-a2c1-8cc8fc89e33e"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="B697894SGQ"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="B697894SGQ"/>
                <display value="Polyethylene Glycol 400"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:34bd50b9-1d9f-4fb0-b430-df433b352d64"/>
    <resource>
      <Ingredient>
        <id value="34bd50b9-1d9f-4fb0-b430-df433b352d64"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="RFW2ET671P"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="RFW2ET671P"/>
                <display value="Hydroxypropyl cellulose (1600000 WAMW)"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:35bfd2e3-7baa-4925-806c-27792531f545"/>
    <resource>
      <Ingredient>
        <id value="35bfd2e3-7baa-4925-806c-27792531f545"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="7SEV7J4R1U"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="7SEV7J4R1U"/>
                <display value="Talc"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:41fe7970-ec5c-40a9-97f1-3f6e6ccf9473"/>
    <resource>
      <Ingredient>
        <id value="41fe7970-ec5c-40a9-97f1-3f6e6ccf9473"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="ETJ7Z6XBU4"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="ETJ7Z6XBU4"/>
                <display value="Silica colloidal anhydrous"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:df6d8f15-6f61-4f0d-a791-ee20833032e2"/>
    <resource>
      <Ingredient>
        <id value="df6d8f15-6f61-4f0d-a791-ee20833032e2"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
          <value value="6OZP39ZG8H"/>
        </identifier>
        <status value="active"/>
        <for>
        <reference value="urn:uuid:89209958-fbe0-43ef-8650-4acd7828dc16"/>
        </for>
        <role>
          <coding>
            <system value="http://hl7.org/fhir/ingredient-role"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <manufacturer>
        </manufacturer>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
                <code value="6OZP39ZG8H"/>
                <display value="polysorbate 80"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:6aa6b6b3-0d67-4136-80ef-36d26b4e6674"/>
    <resource>
      <SubstanceDefinition>
        <id value="6aa6b6b3-0d67-4136-80ef-36d26b4e6674"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="7R9A5P7H32"/>
        </identifier>
        <version value="1"/>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
          </coding>
        </status>
        <description value="Pink, oval, debossing of 'PFE' on one side and '3CL' on the other side."/>
        <molecularWeight>
          <type>
            <text value="exact"/>
          </type>
          <amount>
            <value value="499.53"/>
          </amount>
        </molecularWeight>
        <structure>
          <molecularFormula value="C23H32F3N5O4"/>
        </structure>
        <name>
          <name value="Nirmatrelvir"/>
          <type>
            <coding>
              <system value="http://hl7.org/fhir/substance-name-type"/>
              <code value="Scientific"/>
            </coding>
            <text value="Scientific"/>
          </type>
        </name>
      </SubstanceDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="urn:uuid:5824c778-d827-4c07-ab67-4b06dc222e95"/>
    <resource>
      <SubstanceDefinition>
        <id value="5824c778-d827-4c07-ab67-4b06dc222e95"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"/>
        </meta>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="O3J8G9O825"/>
        </identifier>
        <version value="1"/>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
          </coding>
        </status>
        <description value="White to off white, capsule shaped film coated tablets, debossed with 'H' on one side and 'R9' on other side"/>
        <molecularWeight>
          <type>
            <text value="exact"/>
          </type>
          <amount>
            <value value="720.95"/>
          </amount>
        </molecularWeight>
        <structure>
          <molecularFormula value="C37H48N6O5S2"/>
        </structure>
        <name>
          <name value="Ritonavir"/>
          <type>
            <coding>
              <system value="http://hl7.org/fhir/substance-name-type"/>
              <code value="Scientific"/>
            </coding>
            <text value="Scientific"/>
          </type>
        </name>
      </SubstanceDefinition>
    </resource>
  </entry>
</Bundle>